Days Speakers Posters Session Type Search
Full screen
List At A Glance
Speaker list
Categories Posters
List
List
Type
Thursday 19 September 34 sessions
    07:00 - 20:00 
    REGISTRATION
    08:00 - 10:00 
    ESPE Obesity Working Group (OWG)
    test
    E2
    Chair: Tetyana Chaychenko (Kharkiv, Ukraine)
    WG2
    WG2.1
    Pathogenesis of Insulin Resistance
    Ram Weiss (Jerusalem, Israel)
    WG2.2
    EU vs. non-EU practices on Insulin Resistance assessment (ESPE ObWG project)
    Tetyana Chaychenko (Kharkiv, Ukraine)
    WG2.3
    Insulin function in obese children within the low and high ranges of impaired fasting glycemia
    Claude Marcus (Solna, Sweden)
    WG2.4
    Adolescent type 2 diabetes: Comparing prospective registries
    Reinhard Holl (Ulm, Germany)
    WG2.5
    Youth onset T2D (2018 ISPAD Consensus Guidelines)
    Thomas Reinehr (Datteln, Germany)
    08:00 - 10:00 
    ESPE Working Group on Disorders of Sex Development (DSD)
    E1
    Christa Flück (Bern, Switzerland)
    WG1
    Introduction
    Christa Flück (Bern, Switzerland)
    WG1.1
    Epigenetics and the androgen insensitivity syndrome
    Nadine Hornig (Kiel, Germany)
    WG1.2
    Oligogenic origin of DSD
    Nuria Camats (Barcelona, Spain)
    WG1.3
    Postpubertal outcome of boys born with hypospadias
    Lloyd Tack (Ghent, Belgium)
    WG1.4
    Shared or Shaped Decision-Making in DSD
    Jürg Streuli (Zürich, Switzerland))
    WG1.5
    i-dsd/i-cah
    WG1.6
    Endo-ERN
    Discussion with attendees
    DSD discussion
    Conclusion
    Tülay Güran (Turkey, Istanbul)
    08:00 - 10:00 
    ESPE Working Group on Bone and Growth Plate (BGP)
    F1
    Ciara McDonnell (Dublin, Ireland)
    WG3.1
    Lethal pyridoxin-independent encephalopathy in a case of perinatal hypophosphatasia
    Adalbert Raiman
    WG3.2
    Congenital talipes equinovarus and bowing of femur due to homozygous TRPV6 mutation
    Saygin Abali
    WG3.3
    Mechanisms of vascular calcification and potential treatment implications
    Frank Rutsch (Münster, Germany)
    WG3.4
    Update on BOND
    Klaus Mohnike (Magdeburg, Germany)
    WG3.5
    New insights in growth plate fusion
    Katherine Staines (Edinburgh, Scotland)
    08:00 - 10:00 
    ESPE Working Group on Diabetes Technology (DT)
    F2
    Moshe Philip (Petah Tikva, Israel)
    Introduction
    Moshe Phillip (Petah Tikva, Israel)
    WG4.1
    Impact of hypoglycemia on cognitive function
    Jacques Beltrand (Paris, France))
    WG4.2
    Impact of hyperglycemia on cognitive function
    Jasna Omladič (Ljubljana, Slovenia)
    WG4.3
    Type 2 diabetes and the brain
    Urakami Tatsuhiko (Tokyo, Japan)
    WG4.4
    Fear of hyperglycemia
    Michal Nevo (Petah Tikva, Israel)
    WG4.5
    Time in Range (TIR) - Highlights from the consensus meeting February 2019
    Tadej Battelino (Ljubljana, Slovenia)
    WG4.6
    How technology helps to improve TIR (open and closed loop)
    Boris Kovatchev (Virginia, USA)
    08:00 - 10:00 
    ESPE Working Group on Paediatric and Adolescent Gynaecology (PAG)
    HALL B
    Anne-Simone Parent (Liège, Belgium) & Ken Ong (Cambridge, United Kingdom)
    WG5.1
    Early Origins of PCOS 
    Francis Zegher (Leuven, Belgium)
    WG5.2
    Diagnosis & pharmacological intervention in PCOS
    Lourdes Ibáñez (Barcelona, Spain)
    WG5.3
    Lifestyle intervention in PCOS
    Thomas Reinehr (Datteln, Germany)
    WG5.4
    Androgen Excess in female athletes 
    Angelica Hirschberg (Stockholm, Sweden)
    WG5.5
    Contraception in adolescence
    Kathy Hoeger (Rochester, USA)
    08:00 - 10:00 
    ESPE Working Group on Gender Dysphoria (GD)
    HALL C
    Gary Butler (London, United Kingdom)
    WG6.1
    Assessing competence to consent to physical treatment in transgender adolescents
    Annelou Vries (Amsterdam, The Netherlands)
    WG6.2
    Surgical options for the transfemale
    Mark-Bram Bouman (Amsterdam, The Netherlands)
    WG6.3
    Surgical options for the transmale
    Nim Christopher (London, United Kingdom)
    WG6.4
    Annual General Meeting
    08:00 - 10:00 
    ESPE Working Group on Turner Syndrome (TS)
    HALL A
    Michael Ranke (Tuebingen, Germany), Aneta Gawlik (Katowice, Poland), Malcolm Donaldson (Glasgow, United Kingdom) & Christina Kanaka-Gantenbein (Athens, Greece)
    Introduction
    WG7.1
    Oral versus transdermal induction of puberty - The Turner Working Group of ESPE proposal
    Malcolm Donaldson (Glasgow, United Kingdom)
    WG7.2
    Theoretical and practical implications of transdermal approach to pubertal induction
    Berit Kristrom (Umeå, Sweden))
    Discussion
    WG7.3
    Endocrine management of Turner Syndrome in adolescents and early adulthood
    Melanie Davis (London, United Kingdom)
    WG7.4
    Fertility preservation- technical and ethical aspects
    Kathrin Fleischer (Nijmegen, The Netherlands)
    WG7.5
    Cardiac morbidity and mortality during pregnancy in TS
    Anthonie Duijnhouwers (Nijmegen, The Netherlands)
    Closing remarks
    10:00 - 10:30 
    REFRESHMENT BREAK, POSTERS & EXHIBTION
    Exhibition Area
    10:30 - 10:45 
    OPENING CEREMONY
    HALL A
    10:45 - 11:15 
    PLENARY 1 - RANKL and RANK: Bone and Beyond
    HALL A
    Chairs: Gabriele Häusler (Vienna, Austria) & Agnès Linglart (Paris, France)
    P1
    PL1
    RANKL and RANK: Bone and beyond
    Josef Penninger (Vancouver, Canada)
    11:15 - 11:45 
    ESPE AWARDS - Henning Andersen Prizes
    HALL A
    Mehul Dattani (London, United Kingdom)
    12:00 - 13:30 
    SYMPOSIUM 1
    Novel advances in Diabetes and Obesity
    HALL B
    Chairs: Martin Wabitsch (Ulm, Germany) & Jan Lebl (Prague, Czech Republic)
    S1
    S1.1
    Off the weight curve – dynamics of childhood obesity
    Antje Körner (Leipzig, Germany)
    S1.2
    The gut microbiome and Obesity
    Frank Scott (Denver, USA)
    S1.3
    New developments for treatments in monogenic disorders focusing on setmelanotide trials
    Christine Poitou (Paris, France)
    12:00 - 13:30 
    SYMPOSIUM 2
    What’s new in bone and growth plate research.
    E1
    Chairs: Wolfgang Högler (Linz, Austria) & Dov Tiosano (Haifa, Israel)
    S2
    S2.1
    Longitudinal bone growth: fundamental mechanisms to clinical applications
    Jeffrey Baron (Bethesda, USA)
    S2.2
    Anabolic therapies for osteoporosis in childhood
    Frank Rauch (Montreal, Canada)
    S2.3
    Steroid-Associated Osteoporosis in the Pediatric Population
    Leanne Ward (Ottawa, Canada)
    12:00 - 13:30 
    SYMPOSIUM 3
    Novel insights in our understanding of Disorders of Sex Development: From Genes to Clinical Outcomes
    HALL A
    Chairs: Olaf Hiort (Lubeck, Germany) & Laura Audi (Barcelona, Spain)
    S3.1
    Genetics of DSD – do we understand it?
    Anu Bashamboo (Paris, France)
    S3.2
    Outcomes in DSD – insight from the DSD life study
    Anna Nordenström (Stockholm, Sweden)
    S3.3
    Novel insights into sex determination
    Andy Greenfield (Oxford, United Kingdom)
    12:00 - 13:30 
    SYMPOSIUM 4
    ISPAD/ESPE Symposium - Complications of Type 1 Diabetes
    HALL C
    Chairs: Zdeněk Šumník (Prague, Czech Republic) & Thomas Danne (Hanover, Germany)
    S4.1
    Hypoglycemia in children with T1D: Past, Present, and Future
    David Maahs (Stanford, USA)
    S4.2
    Novel advances in diabetic retinopathy screening and management
    Kim Donaghue (Sydney, Australia)
    S4.3
    Prediction of renal and cardiovascular complications
    Loredana Marcovecchio (Cambridge, United Kingdom)
    12:00 - 13:30 
    ESPE ACTIVITIES
    E2
    ACT1
    eLearning RLC portal
    ACT2
    Science Committee activities
    ACT3
    Education and training activities
    13:30 - 14:45 
    LUNCH, POSTERS & EXHIBITION
    Exhibition Area
    13:45 - 14:45 
    Industry Sponsored Satellite Symposia
    14:45 - 15:45 
    MEET THE EXPERT 1.1
    Holistic approach to the individual with DSD
    HALL B
    MTE1.1
    Holistic approach to the individual with DSD
    Martine Cools (Gent, Belgium)
    14:45 - 15:45 
    MEET THE EXPERT 2.1
    The interpretation of abnormal thyroid function tests in children and adolescents
    HALL C
    MTE2.1
    The interpretation of abnormal thyroid function tests in children and adolescents
    Carla Moran (Cambridge, United Kingdom)
    14:45 - 16:15 
    HOW DO I...
    HOW DO I... SESSION 1
    HALL A
    Chair: John Gregory (Cardiff, United Kingdom)
    HDI1.1
    How Do I... Manage subclinical hypothyroidism
    Mariacarolina Salerno (Naples, Italy)
    HDI1.2
    How Do I... Manage a patient with Prader Willi and GH at transition - do they benefit as adults?
    Maithé Tauber (Toulouse, France)
    HDI1.3
    How do I... Manage a child with insulin resistance
    Francesco Chiarelli (Chieti, Italy)
    14:45 - 16:15 
    FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 2 - Bone, growth plate and mineral metabolism Session 1
    E2
    Chairs: Elisabeth Steichen-Gersdorf (Innsbruck, Austria) & Dirk Schnabel (Berlin, Germany)
    RFC2.1
    Burosumab resulted in better clinical outcomes than continuation with conventional therapy in both younger (1-4 years-old) and older (5-12 years-old) children with X-linked hypophosphatemia
    Wolfgang Högler (Linz, Austria)
    RFC2.2
    Does the treatment with recombinant human growth hormone improve final height in patients affected by X-linked hypophosphatemia?
    Julia André (Le Kremlin Bicêtre, France)
    RFC2.3
    Growth hormone effects on metacarpal bone geometry and bone age in growth hormone-deficient children
    David Martin (Tübingen, Germany)
    RFC2.4
    Bone mass and fracture prevalence in childhood brain cancer survivors 2, 5 or 7 years after off therapy
    Natascia Lorgi (Genova, Italy)
    RFC2.5
    Long term effects of treatment with oxandrolone (Ox) in addition to growth hormone (GH) in girls with Turner syndrome (TS) on bone mineral density in adulthood
    Theo Sas (Rotterdam, The Netherlands)
    RFC2.6
    Impact of pubertal suppression on body composition and bone mineral density in adolescents with gender dysphoria
    Andreas Kyriakou (Glasgow, United Kingdom)
    FC2.1
    Continued improvement in clinical outcomes with burosumab, a fully human anti-FGF23 monoclonal antibody: results from a 3-year, phase 2, clinical trial in children with X-linked hypophosphatemia (XLH)
    Agnès Linglart (Le Kremlin-Bicêtre, France)
    FC2.2
    Benefits of long-term burosumab persist in 11 girls with X-linked hypophosphatemia (XLH) who transitioned into adolescence during the phase 2 CL201 trial
    Annemieke Boot (Groningen, The Netherlands)
    FC2.3
    Higher dose of burosumab is needed for treatment of children with severe forms of X linked hypophosphatemia
    Volha Zhukouskaya (Le Kremlin-Bicêtre, France)
    FC2.4
    New imaging approaches to the quantification of musculoskeletal alterations in X-linked hypophosphatemic rickets (XLH)
    Adalbert Raimann (Vienna, Austria)
    FC2.5
    Age and gender-specific reference data for high-resolution magnetic resonance based musculoskeletal parameters in healthy children and young people
    Huda Elsharkasi (Glasgow, United Kingdom)
    FC2.6
    Validation of a new version of BoneXpert bone age in children with congenital adrenal hyperplasia (CAH), precocious puberty (PP), growth hormone deficiency (GHD), Turner syndrome (TS), and other short stature diagnoses
    David Martin (Tübingen, Germany)
    14:45 - 16:15 
    FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 3 - Multi-system endocrine disorders
    F1
    Chairs: Leena Patel (Manchester, United Kingdom) & Senthil Senniappan (LIverpool, UK)
    RFC3.1
    European Registries For Rare Endocrine Conditions (EuRRECa): results from the pilot phase of The Platform For e-Reporting Of Rare Endocrine Conditions (e-REC)
    Salma Ali (Glasgow, United Kingdom)
    RFC3.2
    Factors affecting loss to follow-up for patients with chronic endocrine conditions during the pediatric period: a cohort study at a reference center for rare diseases
    Laura Atger-Lallier (Paris, France)
    RFC3.3
    The founder homozygous NR5A1 gene mutation p.R103Q causes asplenia and severe XY-DSD and XX-DSD in a Palestinian cohort
    Maha Abdulhadi-Atwan (Hebron, Palestine)
    RFC3.4
    Peripheral glucocorticoid metabolism may reflect resolution of inflammation in Kawasaki disease
    Shuji Sai (Sapporo, Japan)
    RFC3.5
    Evaluation of endothelial function in childhood standard risk acute lymphoblastic leukemia survivors: role of subclinical markers and identification of preventable factors
    Patrizia Bruzzi (Modena, Italy)
    RFC3.6
    Prevalence of endocrine complications in Duchenne muscular dystrophy
    Primož Kotnik (Ljubljana, Slovenia)
    FC3.1
    Germline-derived gain-of-function variants of Gsα-coding GNAS gene identified in nephrogenic syndrome of inappropriate antidiuresis: the first report
    Maki Fukami (Tokyo, Japan)
    FC3.2
    CFTR loss-of-function has effects on microRNAs (miRNAs) that regulate genes involved in growth, glucose metabolism and in fertility in in vitro models of cystic fibrosis
    Francesca Cirillo (Reggio Emilia, Italy)
    FC3.3
    Variability in drug metabolizing cytochrome P450 activities caused by human genetic variations in NADPH cytochrome P450 oxidoreductase (POR)
    Maria Velazquez (Bern, Switzerland)
    FC3.4
    Droplet digital PCR is a useful method for detection of mosaic mutations in patients with McCune–Albright syndrome
    Satoshi Watanabe (Nagasaki, Japan)
    FC3.5
    Evaluation of endocrine late effects in survivors of childhood allogeneic hematopoietic stem cell transplantation in Australia database from 1985 to 2011
    Samantha Lee (Melbourne, Australia)
    FC3.6
    Severe infections contribute to increased risk of early death in patients with apeced
    Joonatan Borchers (Helsinki, Finland)
    14:45 - 16:15 
    FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 1 - Diabetes and Insulin Session 1
    E1
    Chairs: Sabine Hofer (Innsbruck, Austria) & Reinhard Holl (Ulm, Germany)
    RFC1.1
    Low prevalence of maternal microchimerism in Japanese children with type 1 diabetes
    Kikumi Ushijima (Tokyo, Japan)
    RFC1.2
    Gabra5 contributes to sexual dimorphism in POMC neural activity and glucose metabolism
    Zhou Pei (Shanghai, China)
    RFC1.3
    The association between IGF-1 levels and nonalcoholic fatty liver disease (NAFLD) in adolescents with type 2 diabetes
    Jose Morales (Mexico City, Mexico)
    RFC1.4
    Estimation of MODY frequency and prevalent subtypes in pediatric patients by targeted NGS
    Luis Salamanca (Madrid, Spain)
    RFC1.5
    Decreased circulating levels of MOTS-c in individuals with newly diagnosed type 1 diabetes children
    Caiqi Du (Wuhan, China)
    RFC1.6
    An oral trace element supplementation has a potential beneficial effect on glucose homeostasis in transfused patients with β-thalassemia major complicated with diabetes mellitus
    Nancy Elbarbary (Cairo, Egypt)
    FC1.1
    Insulin resistance leads to mitochondrial dysfunction in hepatocyte
    Hong Chen (Hangzhou, China)
    FC1.2
    Three new genes (PTPRD, SYT9, and WSF1) related to Korean maturity-onset diabetes in the young (MODY) children decrease insulin synthesis and secretion in human pancreatic beta cells
    Kyung-Mi Jang (Daegu, Republic of Korea)
    FC1.3
    Next generation sequencing in Greek MODY patients increases diagnostic accuracy and reveals a high percentage of MODY12 cases
    Amalia Sertedaki (Athens, Greece)
    FC1.4
    ABSTRACT WITHDRAWN
    FC1.5
    FADES: A birth cohort to understand the mechanisms underlying accelerated onset of autoimmunity in children with Down’s syndrome
    Georgina Williams (Chippenham, United Kingdom)
    FC1.6
    A novel biochemical marker, fatty acid-binding protein 4, in diabetic ketoacidosis in children
    Noah Gruber (Ramat Gan, Israel)
    16:15 - 16:30 
    REFRESHMENT BREAK, POSTERS AND EXHIBITION
    Exhibition Area
    16:30 - 17:00 
    PLENARY 2
    Light, Body Clocks and Sleep: Biology to New Therapeutics
    HALL A
    Peter Clayton (Manchester, United Kingdom) & Annette Grüters (Heidelberg, Germany)
    PL2
    Light, Body Clocks and Sleep: Biology to New Therapeutics
    Russell Foster (Oxford, United Kingdom)
    17:00 - 18:00 
    MEET THE EXPERT 3.1
    Clinical Practice Guidelines for the Care of Girls and Women with Turner Syndrome: Proceedings from the 2016 Cincinnati International Turner Syndrome Meeting
    HALL B
    MTE3.1
    Clinical practice guidelines for the care of girls and women with Turner syndrome: proceedings from the 2016 Cincinnati International Turner Syndrome Meeting
    Claus Gravholt (Aarhus, Denmark)
    17:00 - 18:00 
    MEET THE EXPERT 4.1
    Klinefelter syndrome - when should testosterone be started
    HALL C
    MTE4.1
    Klinefelter syndrome - when should testosterone be started
    Julia Rohayem (Münster, Germany)
    17:00 - 18:00 
    YEARBOOK OF PAEDIATRIC ENDOCRINOLOGY 1
    HALL A
    Wieland Kiess (Liepzig, Germany)
    YB1.1
    Adrenals
    Evangelia Charmandari (Athens, Greece))
    YB1.2
    Antenatal and Neonatal Endocrinology
    Khalid Hussain (Doha, Qatar))
    YB1.3
    Bone, Growth Plate and Mineral Metabolism
    Ola Nilsson (Stockholm, Sweden))
    YB1.4
    Type 2 Diabetes, Metabolic Syndrome and Lipids
    Orit Pinhas-Hamiel (Tel Aviv, Israel))
    YB1.5
    Editor's Choice
    Ken Ong (Cambridge, United Kingdom))
    17:00 - 18:30 
    FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 5 - Thyroid
    E2
    Chairs: Malgorzata Wasniewska (Messina, Italy) & A. S. Paul Van-Trotsenburg (Amsterdam, The Netherlands)
    RFC5.1
    Hurthle cell carcinoma in childhood retrospective analysis of a large series
    Giorgia Pepe (Messina, Italy)
    RFC5.2
    Ultrasound features of multinodular goiter in DICER1 syndrome
    Marek Niedziela (Poznan, Poland)
    RFC5.3
    Experience of thyroid surgery in children with intraoperative neuromonitoring
    Alexander Anikiev (Moscow, Russian Federation)
    RFC5.4
    Thyroid dysfunction in patients following thymus transplantation in a tertiary centre: a 10-year experience
    Sommayya Aftab (London, United Kingdom)
    RFC5.5
    A novel mutation in the thyroglobulin gene leading to neonatal goiter and congenital hypothyroidism in an Eritrean infant
    Eve Stern (Ramat Gan, Israel)
    RFC5.6
    Complex single nucleotide polymorphisms in SEPINA 7 lead to TBG deficiency
    Fang Yanlan (Hangzhou, China)
    FC5.1
    Randomised trial of block and replace versus dose titration antithyroid drug treatment in children and adolescents with thyrotoxicosis
    Claire Wood (Newcastle upon Tyne, United Kingdom)
    FC5.2
    Lower proportion of CD19+IL-10+ and CD19+CD24hiCD27+ IL-10+, but not CD1d+CD5+CD19+CD24+CD27+ IL-10+ B cells in children with autoimmune thyroid diseases
    Karolina Stożek (Bialystok, Poland)
    FC5.3
    Predominant DICER1 mutations in pediatric follicular thyroid carcinomas
    Young Lee (Seoul, Republic of Korea)
    FC5.4
    Thyroid dysgenesis: exome-wide analysis identifies rare variants in genes involved in thyroid development and cancer
    Stéphanie Larrivée-Vanier (Montreal, Canada)
    FC5.5
    Identification of TRPC4AP as a novel candidate gene causing thyroid dysgenesis
    Daniela Choukair (Heidelberg, Germany)
    FC5.6
    Homozygous loss-of-function mutation in the SLC26A7 gene coding a novel iodide transporter causes goitrous congenital hypothyroidism
    Atsushi Suzuki (Nagoya, Japan)
    17:00 - 18:30 
    FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 4 - Fat, metabolism and obesity
    E1
    Chairs: Julie Chowen (Madrid, Spain) & Moshe Philip (Petah Tikva, Israel)
    RFC4.1
    Expression of miRNAs in circulating exosomes derived from patients with NAFLD
    Junfen Fu (Zhejiang, China)
    RFC4.2
    Circulating exosomal miRNAs in children’s nonalcoholic steatohepatitis and the correlation with serum transaminase and uric acid
    Xuelian Zhou (Hangzhou, China)
    RFC4.3
    Dysregulated gene expression profile in visceral adipose tissue of juvenile Wistar rats with catch-up growth: association with fat expansion and metabolic parameters
    Judit Bassols (Salt, Spain)
    RFC4.4
    The novel phosphatidylinositol-3-kinase (PI3K) inhibitor alpelisib effectively inhibits growth of PTEN haploinsufficient lipoma cells
    Anna Kirstein (Leipzig, Germany)
    RFC4.5
    GDF5 increased white adipose tissue thermogenesis through p38 MAPK signaling pathway in fatty acid-binding protein 4-GDF5 transgenic mice
    Feihong Luo (Shanghai, China)
    RFC4.6
    Appetite suppressing effects of glucoregulatory peptides devoid of nausea
    Christian Roth (Seattle, USA)
    FC4.1
    Involvement of visfatin in adipose tissue fibrosis through modulation of extracellular matrix proteins
    Mitra Nourbakhsh (Tehran, Islamic Republic of Iran)
    FC4.2
    Characterization of the adipose progenitor cell marker MSCA1 in normal weight and obese children
    Martha Hanschkow (Leipzig, Germany)
    FC4.3
    Circulating growth-and-differentiation factor-15 in early life: relation to prenatal and postnatal size
    Marta Díaz (Barcelona, Spain)
    FC4.4
    The rs72613567:TA variant in the hydroxysteroid 17-beta dehydrogenase 13 gene reduces liver damage in obese children
    Anna Sessa (Naples, Italy)
    FC4.5
    Leptin gene methylation status in Egyptian infants
    Omneya Omar (Alexandria, Egypt)
    FC4.6
    Brain satiety responses to a meal in children before and after weight management intervention
    Christian Roth (Seattle, USA)
    18:30 - 20:00 
    Industry-Sponsored Satellite Symposia
    20:00 - 21:30 
    Informal ESPE Networking Event
Friday 20 September 30 sessions
    07:30 - 19:30 
    REGISTRATION
    08:30 - 09:30 
    MEET THE EXPERT 5.1
    Managing endocrinopathies in McCune-Albright Syndrome
    E1
    MTE5.1
    Managing endocrinopathies in McCune-Albright Syndrome
    Daniele Tessaris (Torino, Italy)
    08:30 - 09:30 
    MEET THE EXPERT 6.1
    Management of Diabetic Ketoacidosis
    HALL B
    MTE6.1
    Management of Diabetic Ketoacidosis
    Zdenek Sumnik (Prague, Czech Republic)
    08:30 - 09:30 
    MEET THE EXPERT 7.1
    Management of Graves disease
    E2
    MTE7.1
    Management of Graves disease
    08:30 - 09:30 
    MEET THE EXPERT 8.1
    Management of neonatal hypoglycaemia
    HALL C
    MTE8.1
    Management of neonatal hypoglycaemia
    Klaus Monicke (Magdeburg, Germany)
    08:30 - 09:30 
    MEET THE EXPERT 1.2
    Holistic approach to the individual with DSD
    F1
    MTE1.2
    Holistic approach to the individual with DSD
    Martine Cools (Gent, Belgium)
    08:30 - 09:30 
    YEARBOOK OF PAEDIATRIC ENDOCRINOLOGY 2
    HALL A
    Chair: Feyza Darendeliler (Istanbul, Turkey)
    GPED
    YB2.1
    DSD and gender dysphoria
    Christa Flück (Bern, Switzerland)
    YB2.2
    Growth and Growth Factors
    Danilo Fintini (Rome, Italy)
    YB2.3
    Obesity and Weight Regulation
    Martin Wabitsch (Ulm, Germany))
    YB2.4
    Oncology and Chronic Disease
    Carla Bizzarri (Rome, Italy))
    YB2.5
    Global Health for the Paediatric Endocrinologist
    Jean-Pierre Chanoine (Vancouver, Canada))
    09:30 - 11:00 
    FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 6 - Bone, growth plate and mineral metabolism Session 2
    HALL B
    Chairs: Poonam Dhamaraj (Liverpool, United Kingdom) & Ola Nilsson (Stockholm, Sweden)
    RFC6.1
    EFTUD2 gene deficiency disturbs maturation of osteoblast and inhibits chondrocyte differentiation via activated p53 signaling
    Jing Wu (Shanghai, China)
    RFC6.2
    High levels of LIGHT/TNFSF14 in Prader–Willi syndrome
    Maria Faienza (Bari, Italy)
    RFC6.3
    Increased burden of common risk alleles in children with a significant fracture history
    Despoina Manousaki (Montreal, Canada)
    RFC6.4
    Targeted molecular genetic diagnosis by next generation sequence analysis method and investigation of responsible candidate genes in patients with osteogenesis imperfecta
    Aysun Ata (Izmir, Turkey)
    RFC6.5
    Evaluating genotype–phenotype correlation using an in vitro mutagenesis model in bi-allelic mutations resulting in extreme hypophosphatasia clinical phenotypes
    Suma Uday
    RFC6.6
    Genetic aetiology predicts growth hormone (GH) treatment outcomes in children born small-for-gestational-age with persistent short stature (SGA-SS). Lessons from a single-centre cohort
    Jan Lebl (Prague, Czech Republic)
    FC6.1
    Bone tissue characterization of a mouse model of atypical type VI osteogenesis imperfecta reveals hypermineralization of the bone matrix, elevated osteocyte lacunar density and altered vascularity
    Ghazal Hedjazi (Vienna, Austria)
    FC6.2
    Zone wise cell separation methods comparison, based on relative expression of specific growth plate markers in a pig model
    Alireza Javanmardi (Vienna, Austria)
    FC6.3
    Decreased trabecular bone mineral density and muscle area at the forearm despite improvement in glycaemic control over 3 years after simultaneous pancreas kidney transplantation
    Ondrej Soucek (Prague, Czech Republic)
    FC6.4
    Metabolically unhealthy obese children and adolescents have higher bone mineral density than normal weighted controls but lower than metabolically healthy obeses: no effect of FGF21 levels
    Elif Ozsu (Ankara, Turkey)
    FC6.5
    No change in bone density during 6 months off GH in adolescents with severe GHD at near-adult height
    Roland Schweizer (Tübingen, Germany)
    FC6.6
    Craniosynostosis in inactivating PTH/PTHrP signaling disorder 2: a non-classical feature to consider
    Isolina Riaño-Galan (Oviedo, Spain)
    09:30 - 11:00 
    FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 7 - Diabetes and Insulin Session 2
    HALL C
    Chairs: Birgit Rami-Merhar (Vienna, Austria) & Ram Weiss (Jerusalem, Israel)
    RFC7.1
    Accuracy of glucose sensor estimate of HbA1c in children with type 1 diabetes
    Sarah Ehtisham (Dubai, UAE)
    RFC7.2
    β-cell function and glucose effectiveness in the development of impaired fasting glucose in obese European children and adolescents
    Christian Denzer (Ulm, Germany)
    RFC7.3
    Osteopontin as an early urinary marker of diabetic nephropathy in adolescents with type 1 diabetes mellitus
    Amany Ibrahim (Cairo, Egypt)
    RFC7.4
    Handgrip strength correlates with insulin resistance and the metabolic syndrome in children and adolescents: analysis of the Korean National Health and Nutrition Examination Survey 2014-2016
    Hae Jung (Seoul, Republic of Korea)
    RFC7.5
    Dual diagnosis of type 1 diabetes and ADHD
    Kineret Mazor-Aronovitch (Ramat Gan, Israel)
    RFC7.6
    Health-related quality of life and diabetes control in immigrant and Italian children and adolescents with type 1 diabetes and in their parents
    Barbara Predieri (Modena, Italy)
    FC7.1
    Deployment of a predictive model based on CpG methylation haplotypes analysis on the insulin gene promoter, in a cohort of children and adolescents with type 1 diabetes
    Eleni Kotanidou (Thessaloniki, Greece)
    FC7.2
    Copeptin kinetics and its relationship to osmolality during rehydration for diabetic ketoacidosis in children: an observational study
    Gabor Szinnai (Basel, Switzerland)
    FC7.3
    ABSTRACT WITHDRAWN
    FC7.4
    Metabolic syndrome features in pre-pubertal children born after maternal pre-eclampsia
    Valentina Chiavaroli (Auckland, New Zealand)
    FC7.5
    Is the 1-hour post-load glucose level by 75g oral glucose tolerance test a new risk factor in predicting atherosclerosis?
    Suna Kılınç (Istanbul, Turkey)
    FC7.6
    2017 American Academy of Pediatrics Clinical Practice Guideline: impact on prevalence of arterial hypertension in children and adolescents with type 1 diabetes mellitus
    Axel Dost (Jena, Germany)
    09:30 - 11:00 
    FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 8 - Pituitary, neuroendocrinology and puberty Session 1
    E1
    Chairs: Evelien Gevers (London, United Kingdom) & Juliane Léger (Paris, France)
    RFC8.1
    Trade-off between olfactory bulb and eyeball volume in precocious puberty
    Murat Karaoglan (Gaziantep, Turkey)
    RFC8.2
    Investigation of imprinting alterations in MKRN3 and DLK1 in a cohort of girls with central precocious puberty through specific DNA methylation analysis
    Ana Canton (São Paulo, Brazil)
    RFC8.3
    Central precocious puberty caused by novel mutations in the promoter and 5′-UTR region of the imprinted MKRN3 gene
    Pavlos Fanis (Nicosia, Cyprus)
    RFC8.4
    Evaluation of puberty in patients with Noonan syndrome and mutations in the RAS/MAPK genes
    Alexsandra Malaquias (São Paulo, Brazil)
    RFC8.5
    CHD7 mutations in patients with anosmic or normosmic idiopathic hypogonadotropic hypogonadism
    Leman Kotan (Adana, Turkey)
    RFC8.6
    Growth, pubertal course and long-term outcome of 46,XY boys born with atypical genitalia and low birthweight
    Lloyd Tack (Ghent, Belgium)
    FC8.1
    Hypothalamic AgRP neurons drive endurance in food-restricted mice
    Maria Consolata Miletta (New Haven, USA)
    FC8.2
    Analysis of hypothalamic metabolic circuits after normalization of body weight in mice that had been obese due to high fat diet intake
    Santiago Guerra-Cantera (Madrid, Spain)
    FC8.3
    Absence of central adrenal insufficiency in adults with Prader-Willi syndrome
    Anna Rosenberg (Rotterdam, The Netherlands)
    FC8.4
    Peripheral and hypothalamic alterations in the insulin like growth factor IGF system in response to high fat diet induced weight gain
    Santiago Guerra-Cantera (Madrid, Spain)
    FC8.5
    LGR4-Wnt β-catenin signalling directs GnRH network development, with defects leading to self-limited delayed puberty
    Alessandra Mancini (London, United Kingdom)
    FC8.6
    Source and changes in serum level of kisspeptin in female rats at different developmental stages
    Ahreum Kwon (Seoul, Republic of Korea)
    09:30 - 11:00 
    FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 9 - Fetal, neonatal endocrinology and metabolism (to include hypoglycaemia)
    E2
    Chairs: Pratik Shah (London, United Kingdom) & Jacques Beltrand (Paris, France)
    RFC9.1
    Targeted next-generation sequencing for congenital hypothyroidism with positive neonatal TSH screening results
    Takeshi Yamaguchi (Shimotsuke, Japan)
    RFC9.2
    Age-specific reference values for plasma FT4 and TSH concentrations in healthy, term neonates at day three to seven, and 13 to 15 of life
    J Naafs (Amsterdam, The Netherlands)
    RFC9.3
    Neonatal screening for congenital hypothyroidism analysis of a large cohort of affected patients 1987 2017 and relationship with perfluoroalkylated substances PFAs in north eastern Italy
    Rossella Gaudino (Verona, Italy)
    RFC9.4
    Correlation between genotype and phenotype characteristics in children with congenital hyperinsulinism (CHI) in a specialist centre
    Laura Bosch (London, United Kingdom)
    RFC9.5
    Spectrum of neuro-developmental disorders in children with congenital hyperinsulinism due to activating mutations in GLUD1
    Sommayya Aftab (London, United Kingdom)
    RFC9.6
    Extra uterine growth restriction (EUGR) in very low birth weight infants: growth recovery and neurodevelopment by the corrected age of 2 years old
    Laura Lucaccioni (Modena, Italy)
    FC9.1
    Using CRISPR/Cas9 gene editing to study the molecular mechanisms of congenital hyperinsulinism (CHI)
    Preetha Purushothaman (London, United Kingdom)
    FC9.2
    Heterozygous insulin receptor (INSR) mutation associated with neonatal hyperinsulinaemic hypoglycaemia and familial diabetes mellitus
    Aashish Sethi (Liverpool, United Kingdom)
    FC9.3
    DNA methylation signatures in placenta and umbilical cord: association with maternal obesity
    Judit Bassols (Salt, Spain)
    FC9.4
    Prenatal environment and genetic background influence urinary steroid excretion in monozygotic twins with intra-twin birth-weight differences
    Sandra Schulte (Bonn, Germany)
    FC9.5
    Iodine status of pregnant women and their newborns in the UK – the MABY study
    Malcolm Donaldson (Glasgow, United Kingdom)
    FC9.6
    [18F]F-DOPA-PET/MRI or /CT in children with congenital hyperinsulinism
    Susann Empting (Magdeburg, Germany)
    09:30 - 11:00 
    FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 10 - Sex differentiation, gonads and gynaecology or sex endocrinology
    F1
    Chairs: Ken McElreavey (Paris, France) & Anna Nordenström (Stockholm, Sweden)
    RFC10.1
    Contemporary surgical approach in CAH 46XX – results from the I-DSD/I-CAH registries
    Doris Hebenstreit (Vienna, Austria)
    RFC10.2
    Cryptorchid boys with abrogated mini-puberty display differentially expressed genes involved in sudden infant death syndrome
    Faruk Hadziselimovic (Liestal, Switzerland)
    RFC10.3
    Level of uncertainty in diagnostic evaluation of boys with XY disorders of sex development (DSD)
    Malika Alimussina (Glasgow, United Kingdom)
    RFC10.4
    qPCR screening for Xp21.2 copy number variations in patients with elusive aetiology of 46,XY DSD
    Jakob Meinel (Lübeck, Germany)
    RFC10.5
    Variants in NWD1 gene leading to different degrees of gonadal dysgenesis
    Odile Gaisl (Zurich, Switzerland)
    RFC10.6
    A mutation in the nucleoporin-107 gene causes aberrant Dpp/BMP signaling and XX gonadal dysgenesis
    Tikva Shore (Jerusalem, Israel)
    FC10.1
    Investigating the roles of androgens in male reproductive development, maintenance and function by characterisation of androgen and cortisol deficient 11ß-hydroxylase mutant zebrafish lines
    James Oakes (Sheffield, United Kingdom)
    FC10.2
    The fruit fly, Drosophila melanogaster, as a model to elucidate human differences of sex development (DSD)
    Ivan Mercadé (Fribourg, Switzerland)
    FC10.3
    Mutations in the DEAH-box RNA helicase DHX37 are a frequent cause of 46,XY gonadal dysgenesis and 46,XY testicular regression syndrome
    Ken McElreavey (Paris, France)
    FC10.4
    Loss-of-function and missense mutations in MYRF are a novel cause of autosomal dominant 46,XY Leydig cell hypoplasia and 46,XY gonadal dysgenesis
    Ken McElreavey (Paris, France)
    FC10.5
    Transcriptome analysis of novel Sertoli cell models to highlight potential genes involved in DSD mechanism of disease
    Daniel Gutiérrez (Fribourg, Switzerland)
    FC10.6
    Evaluation of basal and GnRH stimulated AMH levels in central precocious puberty peripheral precocious puberty and premature thelarche
    Nursel Sahin (Ankara, Turkey)
    09:30 - 11:00 
    ERN SESSION
    F2
    Chairs: Anita Hokken-Koelega (Rotterdam, The Netherlands) & Peter Clayton (Manchester, United Kingdom)
    ERN1.1
    Progress in ENDO-ERN
    ERN1.1
    The Lifelong management of Childhood Craniopharyngioma
    Herman Müller (Oldenburg, Germany)
    ERN1.2
    ePAG Representitive
    Arlene Smyth (Glasgow, United Kingdom)
    ERN1.3
    Thyroid Signalling Defects
    Edward Visser (Rotterdam, The Netherlands)
    11:00 - 11:30 
    REFRESHMENT BREAK, POSTERS & EXHIBITION
    Exhibition Area
    11:30 - 12:00 
    ESPE AWARDS - Andrea Prader Prize
    HALL A
    Peter Clayton (Manchester, United Kingdom)
    12:00 - 12:30 
    PLENARY 3
    Glucocorticoid rhythms, stress response and the brain from neonates to adults
    HALL A
    Chairs: Nils Krone (Sheffield, United Kingdom) & Keiichi Ozono (Osaka, Japan)
    PL3
    Glucocorticoid rhythms, stress response and the brain from neonates to adults
    Stafford Lightman (Bristol, United Kingdom)
    12:30 - 13:00 
    ESPE AWARDS
    HALL A
    ESPE Hormone Research in Paediatrics Prizes - Supported by S. Karger AG
    Faisal Ahmed (Glasgow, United Kingdom))
    IFCAH - ESPE Award - Supported by the International Fund Research on Congenital Adrenal Hyperplasia
    Michel Polak (Paris, France))
    ESPE International Outstanding Clinician Award
    Evangelia Charmandari (Athens, Greece))
    Outstanding Clinician Award
    Evangelia Charmandari (Athens, Greece))
    13:00 - 14:30 
    LUNCH, POSTERS & EXHIBITION
    Exhibition Area
    13:15 - 14:15 
    Industry-Sponsored Satellite Symposia
    14:00 - 16:00 
    Global Pediatric Endocrinology and Diabetes (GPED) - The Long Winding Road towards Sustainable Access to Affordable Insulin
    F1
    Chairs: Reiko Horikawa (Japan) & Ganesh Jevalikar (India)
    Introduction
    Jean-Pierre Chanoine (Vancouver, Canada))
    Why are we failing to address the issue of access to insulin in low- and middle- income countries? A global perspective
    David Beran (Geneva, Switzerland)
    Insulin access: from the model list of essential medicines to the patient: new WHO initiatives
    Nicola Magrini (Geneva, Switzerland)
    Access to insulin in China: barriers and opportunities
    Xiaoping Luo (Hubei, China)
    Round table: how to be a leader on insulin access in your country?
    14:30 - 16:00 
    CONTROVERSY
    Does obesity need tertiary care provision?
    HALL A
    Evangelia Charmandari (Athens, Greece)
    CON1.1
    PRO: Does obesity need tertiary care provision?
    Billy White (London, United Kingdom)
    CON1.2
    CON: Does obesity need tertiary care provision?
    Wieland Kiess (Leipzig, Germany)
    14:30 - 16:00 
    SYMPOSIUM 5
    Impact of genomics on growth
    E1
    Chairs: Andrew Dauber (Washington, USA) & Irène Netchine (Paris, France)
    S5.1
    Novel insights into genetic disorders of growth
    Jesús Argente (Madrid, Spain)
    S5.2
    SHOX: From Basic Research to Complex Models and Therapy
    Gudrun ARappold (Heidelberg, Germany)
    S5.3
    The role of KCNQ1in pituitary development
    Taneli Raivio (Helsinki, Finland)
    14:30 - 16:00 
    SYMPOSIUM 6
    Endocrinology meets diversity: Transgender Youth
    HALL B
    Chairs: Sabine Hannema (Leiden, The Netherlands) & Gary Butler (London, United Kingdom)
    S6.1
    Impact of cross-gender hormone treatment on structural brain networks
    Leo Silberbauer (Vienna, Austria)
    S6.2
    Psychiatric comorbidities in Transgender Youth
    Annelou Vries (Amsterdam, The Netherlands)
    S6.3
    Gynecological aspects and fertility issues in transgender adolescents
    Mick van Trotsenburg (St. Pölten, Austria)
    14:30 - 16:00 
    SYMPOSIUM 7 - New Horizens in the Management in Adrenal Insufficiency
    HALL C
    Chairs: Christa Flück (Bern, Switzerland) & Walter Bonfig (Grieskirchen, Austria)
    S7.1
    Novel interventions to treat adrenal insufficiency
    Leonardo Guasti (London, United Kingdom)
    S7.2
    Novel insights into the pathophysiology of adrenal insufficiency syndromes
    John Achermann (London, United Kingdom)
    S7.3
    Widening the horizon - Clinical relevance of steroid hormone pathways
    Stefan Wudy (Giessen, Germany)
    14:30 - 16:30 
    ESPE Nursing and Allied Health Working Group (PENS)
    F2
    Christine Derycke (Brussels, Belgium)
    WG8.1
    New topics in Turner Syndrome
    Siska Verlinde (Brussels, Belgium)
    Discussion
    WG8.2
    Care and Follow up of girls with Turner Syndrome in Northern Sweden
    Discussion
    WG8.3
    What’s New in CAH?
    Discussion
    WG8.4
    Gynaecologic nursing care for CAH
    Louise Williams (London, United Kingdom)
    Discussion
    WG8.5
    Patient perspectives on CAH
    Grace Summer (Leeds, United Kingdom)
    16:00 - 16:30 
    PLENARY 4
    HPG -Nutrition and the hypothalamo-pituitary-gonadal axis
    HALL A
    Chairs: Anders Juul (Copenhagen, Denmark) & Luca Persani (Milan, Italy)
    PL4
    HPG -Nutrition and the hypothalamo-pituitary-gonadal axis
    Manuel Tena-Sempere (Córdoba, Spain)
    16:30 - 16:45 
    REFRESHMENT BREAK, POSTERS & EXHIBITION
    Exhibition Area
    16:45 - 18:15 
    Industry-Sponsored Satellite Symposia
    17:00 - 18:00 
    NOVEL ADVANCES 1
    Stem cell reprogramming, IPS cells
    HALL B
    Chair: Nicolas de Roux (Paris, France)
    NA1
    Single Cell technologies
    Karine Rizzoti (London, United Kingdom)
    18:15 - 19:30 
    ESPE ANNUAL BUSINESS MEETING
    F2
Saturday 21 September 32 sessions
    07:30 - 18:30 
    REGISTRATION
    08:00 - 09:00 
    MEET THE EXPERT 2.2
    The Interpretation of Abnormal Thyroid Function Tests in Children and Adolescents
    E1
    MTE2.2
    The interpretation of abnormal thyroid function tests in children and adolescents
    Carla Moran (Cambridge, United Kingdom)
    08:00 - 09:00 
    MEET THE EXPERT 3.2
    Clinical Practice Guidelines for the Care of Girls and Women with Turner Syndrome: Proceedings from the 2016 Cincinnati International Turner Syndrome Meeting
    HALL B
    MTE3.2
    Clinical practice guidelines for the care of girls and women with Turner syndrome: proceedings from the 2016 Cincinnati International
    Claus Gravholt (Aarhus, Denmark)
    08:00 - 09:00 
    MEET THE EXPERT 4.2
    Klinefelter syndrome - when should testosterone be started
    E2
    MTE4.2
    Klinefelter syndrome - when should testosterone be started
    Julia Rohayem (Münster, Germany)
    08:00 - 09:00 
    MEET THE EXPERT 5.2
    Managing endocrinopathies in McCune-Albright Syndrome
    HALL C
    MTE5.2
    Managing endocrinopathies in McCune-Albright Syndrome
    Daniele Tessaris (Torino, Italy)
    08:00 - 09:00 
    YEARBOOK OF PAEDIATRIC ENDOCRINOLOGY 3
    HALL A
    YB3.1
    Pituitary and Neuroendocrinology
    Nicolas Roux (Paris, France))
    YB3.2
    Puberty
    Anne-Simone Parent (Liège, Belgium))
    YB3.3
    Thyroid
    Gabor Szinnai (Basel, Switzerland)
    YB3.4
    Type 1 Diabetes
    Wieland Kiess (Leipzig, Germany)
    YB3.5
    The Year in Science & Medicine
    Ze'ev Hochberg (Haifa, Isreal))
    09:00 - 10:30 
    HOW DO I...
    HOW DO I...SESSION 2
    HALL A
    Chair: Marco Cappa (Rome, Italy)
    HDI2.1
    How do I…. Manage micropenis in a child?
    Silvano Bertelloni (Pisa, Italy)
    HDI2.2
    How Do I... Diagnosing growth hormone resistance?
    Marie-José Walenkamp (Amsterdam, The Netherlands)
    HDI2.3
    How Do I... Manage of an asymptomatic child with T1D and transglutaminase positivity?
    Elke Frohlich-Reiterer (Graz, Austria)
    09:00 - 10:30 
    FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 11 - Pituitary, neuroendocrinology and metabolism Session 2
    HALL B
    Chairs: Gerhard Binder (Tübingen, Germany) & Katharina Main (Copenhagen, Denmark)
    RFC11.1
    National United Kingdom evidence- and consensus-based guidelines for the investigation, treatment and long-term follow-up of paediatric craniopharyngioma
    Hoong-Wei Gan
    RFC11.2
    Prevalence and predicting factors of endocrine dysfunction in children with NF1 and optic gliomas
    Anna Grandone (Naples, Italy)
    RFC11.3
    Polycystic ovarian syndrome in adolescents: utilising discovery proteomics and the search to identify novel non-invasive biomarkers
    Harriet Gunn (London, United Kingdom)
    RFC11.4
    Increased adrenal and testicular androgen concentrations before puberty and in early puberty correlate to adult height outcomes in males with Silver–Russell syndrome
    Kjersti Kvernebo-Sunnergren (Gothenburg, Sweden)
    RFC11.5
    IGF-1 serum concentrations and growth in children with congenital leptin deficiency (CLD) before and after replacement therapy with metreleptin
    Marianna Beghini (Ulm, Germany)
    RFC11.6
    Final height reduction in transgender adolescent girls: a case series
    Ilse Hellinga (Amsterdam, The Netherlands)
    FC11.1
    Phenotypic characterization of a large pediatric cohort of patients with genetic forms of congenital hypopituitarism
    Cecilia Cionna (London, United Kingdom)
    FC11.2
    A novel minor spliceosome defect associated with growth hormone deficiency GHD and primary ovarian insufficiency POI
    Leyla Akin (Kayseri, Turkey)
    FC11.3
    A novel genetic aetiology for familial neonatal central diabetes insipidus
    Eran Lavi (Jerusalem, Israel)
    FC11.4
    Whole exome sequencing in a familial case of adamantinomatous craniopharyngioma revealed two hits affecting Wnt-signaling pathway
    Anatoly Tiulpakov (Moscow, Russian Federation)
    FC11.5
    Survival, endocrine disorders and quality of life in 135 children with craniopharyngioma after surgical or combined treatment
    Nadia Mazerkina (Moscow, Russian Federation)
    FC11.6
    Pubertal timing in parents is associated with timing of pubertal milestones in offspring of concordant sex – but only inconsistently with milestones in offspring of discordant sex
    Alexander Busch (Copenhagen, Denmark)
    09:00 - 10:30 
    FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 12 - Growth and syndromes (to include Turner syndrome)
    HALL C
    Chairs: Sandro Loche (Cagliari, Italy) & Helen Storr (London, United Kingdom)
    RFC12.1
    Karyotyping of oocytes, granulosa cells and stromal cells in the ovarian tissue from patients with Turner syndrome: a pilot study
    Sapthami Nadesapillai (Nijmegen, The Netherlands)
    RFC12.2
    Treatment with growth hormone increases Klotho concentration in patients with Turner syndrome
    Beata Wikiera (Wroclaw, Poland)
    RFC12.3
    Imprinting defects and copy number variations in short children born small for gestational age
    Masayo Kagami (Tokyo, Japan)
    RFC12.4
    NIPBL is required for postnatal growth and neural development
    Xiaohui Wu (Hangzhou, China)
    RFC12.5
    Cognitive and neuroradiological assessments in Silver Russell patients
    Giuseppa Patti (Genova, Italy)
    RFC12.6
    Exploring the usefulness of a new type of pubertal height reference based on growth aligned or onset of pubertal growth
    Anton Holmgren (Gothenburg, Sweden)
    FC12.1
    Increasing knowledge in IGF1R defects: lessons from 20 new patients.
    Eloïse Giabicani (Paris, France)
    FC12.2
    NPR2 gene mutations were found in 5.4% children with familial short stature
    Lukas Plachy (Prague, Czech Republic)
    FC12.3
    Growth hormone treatment in adults with Prader–Willi syndrome has sustained positive effects on body composition
    Layla Damen (Rotterdam, The Netherlands)
    FC12.4
    Integration of transcriptomic and epigenomic data in childhood identifies a subset of individuals born small for gestational age (SGA) with “catch-up” growth who become pre-hypertensive in early adulthood
    Terence Garner (Manchester, United Kingdom)
    FC12.5
    Integrated analysis of baseline blood transcriptome and genome identifies clusters of Turner syndrome patients with different responses to recombinant human growth hormone
    Adam Stevens (Manchester, United Kingdom)
    FC12.6
    An integrated systems biology analysis of the genome, epigenome and transcriptome identifies a distinct pattern of hypermethylation associated with low childhood growth
    Terence Garner (Manchester, United Kingdom)
    09:00 - 10:30 
    FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 13 - Adrenals and HP axis
    E1
    Chairs: Stefan Wudy (Gießen, Germany) & Angela Huebner (Dresden, Germany)
    RFC13.1
    Children and adolescents in the United States with congenital adrenal hyperplasia are not at increased risk for attention-deficit/hyperactivity disorder
    Lauren Harasymiw (Minneapolis, USA)
    RFC13.2
    Development of novel non-invasive strategies for monitoring of treatment control in patients with congenital adrenal hyperplasia
    Irina-Alexandra Bacila
    RFC13.3
    Establishment of reference intervals for hair cortisol in healthy children aged 0-18 years using mass spectrometric analysis
    Ineke Kruijff (Nieuwegein, The Netherlands)
    RFC13.4
    Loss-of-function NNT mutations impair antioxidants mechanisms and decreases cortisol secretion in patients with familial glucocorticoid deficiency
    Aline Bodoni (Ribeirao Preto, Brazil)
    RFC13.5
    Genetics of familial glucocorticoid deficiency over the decades: phenotypic variability and associated features
    C Smith (London, United Kingdom)
    RFC13.6
    Inhibitory effects of curcuminoids on the enzymes from the steroidogenic pathway
    Patricia Castaño (Bern, Switzerland)
    FC13.1
    Peptide MC2R antagonists as a new potential therapeutic approach for congenital adrenal hyperplasia
    Angela Huebner (Dresden, Germany)
    FC13.2
    Sexual dimorphism in cortisol production and metabolism throughout pubertal development: a longitudinal study
    Britt Keulen (Amsterdam, The Netherlands)
    FC13.3
    YAP1-HIPPO pathway as a novel prognostic marker and therapeutic target for pediatric patients with adrenocortical tumors (ACT)
    Candy More (São Paulo, Brazil)
    FC13.4
    Biphasic glucocorticoid rhythm in one-month old infants: reflection of a developing HPA-axis?
    Jonneke Hollanders (Amsterdam, The Netherlands)
    FC13.5
    SGPL1 deficiency leads to downregulation of key enzymes within the steroidogenic pathway
    Avinaash Maharaj
    FC13.6
    Insights into the role of cortisol in the formation of the Clock/Bmal1 complex and its interaction with dsDNA, via molecular dynamics simulations
    Nicolas Nicolaides (Athens, Greece)
    09:00 - 10:30 
    FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 14 - GH and IGF1
    E2
    Chairs: Ivo Arnhold (Sao Paulo, Brazil) & Joachim Woelfle (Erlangen, Germany)
    RFC14.1
    Papp-a2 deficiency results in sex-dependent modifications in hypothalamic regulation of energy homeostasis
    Jesús Argente (Madrid, Spain)
    RFC14.2
    Deciphering genetic aetiology among children born small-for-gestational-age with persistent short stature (SGA-SS): phenotypic characteristics at diagnosis in a large single-centre cohort
    Ledjona Toni (Prague, Czech Republic)
    RFC14.3
    MicroRNAs change and target key regulatory genes involved in longitudinal growth in patients with idiopathic isolated growth hormone deficiency (IGHD) on growth hormone (GH) treatment
    Maria Street (Reggio Emilia, Italy)
    RFC14.4
    GHR transcript heterogeneity may explain the phenotypic variability in patients with homozygous GHR pseudoexon (6Ψ) mutation
    Sumana Chatterjee
    RFC14.5
    Bioactive IGF-I concentration compared to total IGF-I concentration before and after 1 year of high-dose growth hormone in short children born small for gestational age – North European SGA Study (NESGAS)
    Rikke Jensen (Copenhagen, Denmark)
    RFC14.6
    Growth hormone deficiency (GHD): assessing burden of disease in children and adolescents: the growth hormone deficiency – child impact measure (GHD-CIM)
    Meryl Brod (Mill Valley, USA)
    FC14.1
    Inhibition of IGF1R by IGF1R/IR inhibitor OSI906 as a targeted therapy for glioblastoma: in vitro & in vivo studies
    Ayelen Martin (Buenos Aires, Argentina)
    FC14.2
    Pubertal onset in 1572 girls with short, normal and tall stature: associations to height, serum IGF-I and PAPP-A2 genotypes
    Emmie Upners (Copenhagen, Denmark)
    FC14.3
    Papp-a2 deficiency induces sex-specific changes in hydroxyapatite-(CaOH) crystallinity and the effects of IGF-1 on bone composition in adult mice
    Jesús Argente (Madrid, Spain)
    FC14.4
    Once-weekly TransCon hGH vs. Daily hGH in pediatric growth hormone deficiency: the phase 3 heiGHt trial
    Elpis Vlachopapadopoulou (Athens, Greece)
    FC14.5
    Once-weekly somapacitan vs daily growth hormone (Norditropin®) in childhood growth hormone deficiency: One-year results from a randomised phase 2 trial
    Lars Sävendahl (Stockholm, Sweden)
    FC14.6
    Effects of 8 years of growth hormone treatment on cognition in children with Prader–Willi syndrome
    Anita Hokken-Koelega (Rotterdam, The Netherlands)
    09:00 - 10:30 
    FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 15 - Late Breaking Session
    F1
    Chairs: Lou Metherell (London, UK) & Yves Le-Bouc (Paris, France)
    RFC15.1
    Preclinical studies of acrodysostosis gene aav therapy in a knock in r368 x prkar1 a mouse model
    Catherine Stunff (Le Kremlin-Bicêtre, France)
    RFC15.2
    BMP4 mutations as a novel cause of normosmic hypogonadotropic hypogonadism
    A Topaloglu (Jackson, USA)
    RFC15.3
    Metformin treatment affects ACTH receptor activation and downstream signaling: a potential treatment for ACTH excess disorders and management of hyperandrogenic states
    Shaheena Parween (Bern, Switzerland)
    RFC15.4
    Clinical and genetic characterization of 148 patients with persistent or transient congenital hyperinsulinism: a population-based study in Finns
    Jonna Männistö (Kuopio, Finland)
    RFC15.5
    De novo missense mutation in SP7 in a patient with cranial hyperostosis, long bone fragility, and increased osteoblast number
    Adalbert Raimann (Vienna, Austria)
    RFC15.6
    Absence of puberty and estrogen resistance by estrogen alpha receptor inactivation in two sisters: a mutation for variable phenotypic severity
    Clémence Delcour (Paris, France)
    FC15.1
    DLG2 mutations in patients with delayed or absent puberty
    Youn Jee (Bethesda, USA)
    FC15.2
    HDAC4 mutations cause diabetes and induce β-cell FoxO1 nuclear exclusion
    Klemens Raile (Berlin, Germany)
    FC15.3
    The P450 side-chain cleavage isozyme cyp11a2 facilitates interrenal and gonadal steroid hormone biosynthesis in developing and adult zebrafish
    James Oakes (Sheffield, United Kingdom)
    FC15.4
    Defects in the GnRH neuroendocrine network affect the timing of puberty
    Tansit Saengkaew (London, United Kingdom)
    FC15.5
    Effects of Bifidobacterium animalis subsp. lactis on children with Prader–Willi syndrome: a randomized, double-blind, placebo-controlled, crossover trial
    Marta Ramon-Krauel (Barcelona, Spain)
    FC15.6
    Leptin influences the down-regulation of UCP-1 expression in brown adipose tissue during negative energy balance
    Vicente Barrios (Madrid, Spain)
    10:30 - 11:00 
    REFRESHMENT BREAK, POSTERS & EXHIBITION
    Exhibition Area
    11:00 - 11:30 
    PLENARY 5
    How to reduce waste and increase value in translational biomedical research
    HALL A
    Chairs: Stefan Riedl (Vienna, Austria) & Faisal Ahmed (Glasgow, United Kingdom)
    PL5
    How to reduce waste and increase value in translational biomedical research
    Ulrich Dirnagl (Berlin, Germany)
    11:30 - 12:00 
    ESPE AWARDS
    ESPE Research Award
    HALL A
    Agnès Linglart (Paris, France)
    12:00 - 12:30 
    PLENARY 6
    Pituitary Gigantism - an update
    HALL A
    Chairs: Mehul T. Dattani (London, United Kingdom) & Rasa Verkauskiene (Kaunas, Lithuania)
    PL6
    Pituitary Gigantism - an update
    Albert Beckers (Liège, Belgium)
    12:30 - 14:00 
    LUNCH, POSTERS & EXHIBITION
    Exhibition Area
    12:45 - 13:45 
    Industry Sponsored Satellite Symposia
    14:00 - 15:00 
    YOUNG INVESTIGATORS SESSION
    F1
    Faisal Ahmed (Glasgow, United Kingdom)
    YI1.1
    In search for novel monitoring tools to detect chronic over- or under-treatment in children with CAH
    Erica Akker (Rotterdam, The Netherlands)
    YI1.2
    The role of the gut microbiome in metabolism
    Valentina Chiavaroli (Auckland, New Zealand)
    ESPE Young Investigator Awards
    14:00 - 15:00 
    MEET THE EXPERT 6.2
    Management of Diabetic Ketoacidosis
    HALL B
    MTE6.2
    Management of Diabetic Ketoacidosis
    Zdenek Sumnik (Prague, Czech Republic)
    14:00 - 15:00 
    MEET THE EXPERT 7.2
    Management of Graves disease
    E2
    MTE7.2
    Management of Graves disease
    Tim Cheetham
    14:00 - 15:00 
    MEET THE EXPERT 8.2
    Management of neonatal hypoglycaemia
    HALL C
    MTE8.2
    Management of neonatal hypoglycaemia
    Klaus Monicke (Magdeburg, Germany)
    14:00 - 15:00 
    NOVEL ADVANCES 2
    Genetic imprinting analysis in clinical practice
    E1
    NA2
    Genetic imprinting analysis in clinical practice
    Deborah Mackay (Southampton, United Kingdom)
    15:00 - 15:30 
    REFRESHMENT BREAK, POSTERS & EXHIBITION
    Exhibition Area
    15:30 - 17:00 
    SYMPOSIUM 8
    Autoimmunity: From diagnosis to treatment
    E1
    Chairs: Elke Froehlich-Reiterer (Graz, Austria) & Loredana Marcovecchio (Cambridge, United Kingdom)
    S8.1
    New autoantibodies in endocrine autoimmunity development: Lessons from APECED
    Pärt Peterson (Tartu, Estonia)
    S8.2
    Novel monogenic forms of autoimmune diabetes
    Sarah Flanagan (Exeter, United Kingdom)
    S8.3
    Bone marrow transplant for genetically determined autoimmunity
    Mary Slatter (London, United Kingdom)
    15:30 - 17:00 
    SYMPOSIUM 9
    Heterogeneity of paediatric diabetes
    HALL B
    Chairs: Stepanka Pruhova (Prague, Czech Republic) & Francesco Chiarelli (Chieti, Italy)
    S9.1
    Diversity in monogenic diabetes management and prognosis
    Pål Njølstad (Bergen, Norway)
    S9.2
    Diagnostic and therapeutic implications of double diabetes
    Tatsuhiko Urakami (Tokyo, Japan)
    S9.3
    Obesity and T2 diabetes: How to find a population at risk
    Silva Arslanian (Pittsburgh, USA)
    15:30 - 17:00 
    SYMPOSIUM 10
    Brain development and sex: Is it chromosomes or hormones?
    E2
    Chair: Cheri Deal (Montreal, Canada)
    S10.1
    Multifaceted origins of sex differences in the brain
    Erin Reinl (Maryland, USA)
    S10.2
    The pubertal brain
    Anne-Lise Goddings (London, United Kingdom)
    S10.3
    How hormones impact on emotion and cognition --- new insights from Magnetic resonance imaging
    Sven Müller (Ghent, Belgium)
    15:30 - 17:00 
    SYMPOSIUM 11
    Recent advances in our understanding of Hypogonadotrophic hypogonadism
    HALL C
    Chairs: Leo Dunkel (London, United Kingdom) & Mohamad Maghnie (Genoa, Italy)
    S11.1
    Novel insights into the molecular basis of hypogonadotrophic hypogonadism
    Ravikumar Balasubramanian (Boston, USA)
    S11.2
    Novel insights into the regulation of reproduction from 3D imaging of the GnRH and kisspeptin neuronal populations
    Paolo Giacobini (Milan, Italy)
    S11.3
    Novel insights into the role of semaphorin signalling in GnRH neuron development and failure
    Anna Cariboni (Milan, Italy)
    17:00 - 17:30 
    ESPE AWARDS
    HALL A
    ESPE International Award
    Peter Clayton (Manchester, United Kingdom))
    ESPE President Poster Awards
    Gabriele Häusler (Vienna, Austria))
    17:30 - 18:00 
    PLENARY 7
    Novel advances in artificial pancreas development
    HALL A
    Chairs: Asma Deeb (Abu Dhabi, UAE) & Tadej Battelino (Ljubljana, Slovenia)
    PL7
    Novel advances in artificial pancreas development
    Boris Kovatchev (Virginia, USA)
    18:00 - 18:15 
    ESPE 2019 CLOSING CEREMONY
    HALL A
    19:00 - 00:00 
    THE ESPE EVENING
    THE CITY HALL
Carla Moran
Carla Moran
MTE2.1
Thu 19 14:45 MEET THE EXPERT 2.1
The interpretation of abnormal thyroid function tests in children and adolescents
Carla Moran
Carla Moran
MTE2.2
Sat 21 08:00 MEET THE EXPERT 2.2
The interpretation of abnormal thyroid function tests in children and adolescents
John Achermann
John Achermann
S7.2
Fri 20 14:30 SYMPOSIUM 7 - New Horizens in the Management in Adrenal Insufficiency
Novel insights into the pathophysiology of adrenal insufficiency syndromes
Karine Rizzoti
Karine Rizzoti
NA1
Fri 20 17:00 NOVEL ADVANCES 1
Single Cell technologies
Irina-Alexandra Bacila
Irina-Alexandra Bacila
RFC13.2
Sat 21 09:00 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 13 - Adrenals and HP axis
Development of novel non-invasive strategies for monitoring of treatment control in patients with congenital adrenal hyperplasia
Hoong-Wei Gan
Hoong-Wei Gan
RFC11.1
Sat 21 09:00 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 11 - Pituitary, neuroendocrinology and metabolism Session 2
National United Kingdom evidence- and consensus-based guidelines for the investigation, treatment and long-term follow-up of paediatric craniopharyngioma
Sumana Chatterjee
Sumana Chatterjee
RFC14.4
Sat 21 09:00 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 14 - GH and IGF1
GHR transcript heterogeneity may explain the phenotypic variability in patients with homozygous GHR pseudoexon (6Ψ) mutation
Avinaash Maharaj
Avinaash Maharaj
FC13.5
Sat 21 09:00 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 13 - Adrenals and HP axis
SGPL1 deficiency leads to downregulation of key enzymes within the steroidogenic pathway
Suma Uday
Suma Uday
RFC6.5
Fri 20 09:30 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 6 - Bone, growth plate and mineral metabolism Session 2
Evaluating genotype–phenotype correlation using an in vitro mutagenesis model in bi-allelic mutations resulting in extreme hypophosphatasia clinical phenotypes
Tim Cheetham
Tim Cheetham
MTE7.2
Sat 21 14:00 MEET THE EXPERT 7.2
Management of Graves disease
Ram Weiss
Ram Weiss
WG2.1
Thu 19 08:00 ESPE Obesity Working Group (OWG)
Pathogenesis of Insulin Resistance
Tetyana Chaychenko
Tetyana Chaychenko
WG2.2
Thu 19 08:00 ESPE Obesity Working Group (OWG)
EU vs. non-EU practices on Insulin Resistance assessment (ESPE ObWG project)
Claude Marcus
Claude Marcus
WG2.3
Thu 19 08:00 ESPE Obesity Working Group (OWG)
Insulin function in obese children within the low and high ranges of impaired fasting glycemia
Reinhard Holl
Reinhard Holl
WG2.4
Thu 19 08:00 ESPE Obesity Working Group (OWG)
Adolescent type 2 diabetes: Comparing prospective registries
Thomas Reinehr
Thomas Reinehr
WG2.5
Thu 19 08:00 ESPE Obesity Working Group (OWG)
Youth onset T2D (2018 ISPAD Consensus Guidelines)
Thomas Reinehr
Thomas Reinehr
WG5.3
Thu 19 08:00 ESPE Working Group on Paediatric and Adolescent Gynaecology (PAG)
Lifestyle intervention in PCOS
Christa Flück
Christa Flück
Thu 19 08:00 ESPE Working Group on Disorders of Sex Development (DSD)
Introduction
Christa Flück
Christa Flück
YB2.1
Fri 20 08:30 YEARBOOK OF PAEDIATRIC ENDOCRINOLOGY 2
DSD and gender dysphoria
Nadine Hornig
Nadine Hornig
WG1.1
Thu 19 08:00 ESPE Working Group on Disorders of Sex Development (DSD)
Epigenetics and the androgen insensitivity syndrome
Nuria Camats
Nuria Camats
WG1.2
Thu 19 08:00 ESPE Working Group on Disorders of Sex Development (DSD)
Oligogenic origin of DSD
Lloyd Tack
Lloyd Tack
WG1.3
Thu 19 08:00 ESPE Working Group on Disorders of Sex Development (DSD)
Postpubertal outcome of boys born with hypospadias
Lloyd Tack
Lloyd Tack
RFC8.6
Fri 20 09:30 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 8 - Pituitary, neuroendocrinology and puberty Session 1
Growth, pubertal course and long-term outcome of 46,XY boys born with atypical genitalia and low birthweight
Jürg Streuli
Jürg Streuli
WG1.4
Thu 19 08:00 ESPE Working Group on Disorders of Sex Development (DSD)
Shared or Shaped Decision-Making in DSD
DSD discussion
DSD discussion
Thu 19 08:00 ESPE Working Group on Disorders of Sex Development (DSD)
Discussion with attendees
Tülay Güran
Tülay Güran
Thu 19 08:00 ESPE Working Group on Disorders of Sex Development (DSD)
Conclusion
Adalbert Raiman
Adalbert Raiman
WG3.1
Thu 19 08:00 ESPE Working Group on Bone and Growth Plate (BGP)
Lethal pyridoxin-independent encephalopathy in a case of perinatal hypophosphatasia
Saygin Abali
Saygin Abali
WG3.2
Thu 19 08:00 ESPE Working Group on Bone and Growth Plate (BGP)
Congenital talipes equinovarus and bowing of femur due to homozygous TRPV6 mutation
Frank Rutsch
Frank Rutsch
WG3.3
Thu 19 08:00 ESPE Working Group on Bone and Growth Plate (BGP)
Mechanisms of vascular calcification and potential treatment implications
Klaus Mohnike
Klaus Mohnike
WG3.4
Thu 19 08:00 ESPE Working Group on Bone and Growth Plate (BGP)
Update on BOND
Katherine Staines
Katherine Staines
WG3.5
Thu 19 08:00 ESPE Working Group on Bone and Growth Plate (BGP)
New insights in growth plate fusion
Moshe Phillip
Moshe Phillip
Thu 19 08:00 ESPE Working Group on Diabetes Technology (DT)
Introduction
Jacques Beltrand
Jacques Beltrand
WG4.1
Thu 19 08:00 ESPE Working Group on Diabetes Technology (DT)
Impact of hypoglycemia on cognitive function
Jasna Omladič
Jasna Omladič
WG4.2
Thu 19 08:00 ESPE Working Group on Diabetes Technology (DT)
Impact of hyperglycemia on cognitive function
Urakami Tatsuhiko
Urakami Tatsuhiko
WG4.3
Thu 19 08:00 ESPE Working Group on Diabetes Technology (DT)
Type 2 diabetes and the brain
Michal Nevo
Michal Nevo
WG4.4
Thu 19 08:00 ESPE Working Group on Diabetes Technology (DT)
Fear of hyperglycemia
Tadej Battelino
Tadej Battelino
WG4.5
Thu 19 08:00 ESPE Working Group on Diabetes Technology (DT)
Time in Range (TIR) - Highlights from the consensus meeting February 2019
Boris	Kovatchev
Boris Kovatchev
WG4.6
Thu 19 08:00 ESPE Working Group on Diabetes Technology (DT)
How technology helps to improve TIR (open and closed loop)
Francis Zegher
Francis Zegher
WG5.1
Thu 19 08:00 ESPE Working Group on Paediatric and Adolescent Gynaecology (PAG)
Early Origins of PCOS 
Lourdes Ibáñez
Lourdes Ibáñez
WG5.2
Thu 19 08:00 ESPE Working Group on Paediatric and Adolescent Gynaecology (PAG)
Diagnosis & pharmacological intervention in PCOS
Angelica Hirschberg
Angelica Hirschberg
WG5.4
Thu 19 08:00 ESPE Working Group on Paediatric and Adolescent Gynaecology (PAG)
Androgen Excess in female athletes 
Kathy Hoeger
Kathy Hoeger
WG5.5
Thu 19 08:00 ESPE Working Group on Paediatric and Adolescent Gynaecology (PAG)
Contraception in adolescence
Annelou Vries
Annelou Vries
WG6.1
Thu 19 08:00 ESPE Working Group on Gender Dysphoria (GD)
Assessing competence to consent to physical treatment in transgender adolescents
Annelou Vries
Annelou Vries
S6.2
Fri 20 14:30 SYMPOSIUM 6
Psychiatric comorbidities in Transgender Youth
Mark-Bram Bouman
Mark-Bram Bouman
WG6.2
Thu 19 08:00 ESPE Working Group on Gender Dysphoria (GD)
Surgical options for the transfemale
Nim Christopher
Nim Christopher
WG6.3
Thu 19 08:00 ESPE Working Group on Gender Dysphoria (GD)
Surgical options for the transmale
Malcolm Donaldson
Malcolm Donaldson
WG7.1
Thu 19 08:00 ESPE Working Group on Turner Syndrome (TS)
Oral versus transdermal induction of puberty - The Turner Working Group of ESPE proposal
Malcolm Donaldson
Malcolm Donaldson
FC9.5
Fri 20 09:30 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 9 - Fetal, neonatal endocrinology and metabolism (to include hypoglycaemia)
Iodine status of pregnant women and their newborns in the UK – the MABY study
Berit Kristrom
Berit Kristrom
WG7.2
Thu 19 08:00 ESPE Working Group on Turner Syndrome (TS)
Theoretical and practical implications of transdermal approach to pubertal induction
Melanie Davis
Melanie Davis
WG7.3
Thu 19 08:00 ESPE Working Group on Turner Syndrome (TS)
Endocrine management of Turner Syndrome in adolescents and early adulthood
Kathrin Fleischer
Kathrin Fleischer
WG7.4
Thu 19 08:00 ESPE Working Group on Turner Syndrome (TS)
Fertility preservation- technical and ethical aspects
Anthonie Duijnhouwers
Anthonie Duijnhouwers
WG7.5
Thu 19 08:00 ESPE Working Group on Turner Syndrome (TS)
Cardiac morbidity and mortality during pregnancy in TS
Josef Penninger
Josef Penninger
PL1
Thu 19 10:45 PLENARY 1 - RANKL and RANK: Bone and Beyond
RANKL and RANK: Bone and beyond
Antje Körner
Antje Körner
S1.1
Thu 19 12:00 SYMPOSIUM 1
Off the weight curve – dynamics of childhood obesity
Frank Scott
Frank Scott
S1.2
Thu 19 12:00 SYMPOSIUM 1
The gut microbiome and Obesity
Christine Poitou
Christine Poitou
S1.3
Thu 19 12:00 SYMPOSIUM 1
New developments for treatments in monogenic disorders focusing on setmelanotide trials
Jeffrey Baron
Jeffrey Baron
S2.1
Thu 19 12:00 SYMPOSIUM 2
Longitudinal bone growth: fundamental mechanisms to clinical applications
Frank Rauch
Frank Rauch
S2.2
Thu 19 12:00 SYMPOSIUM 2
Anabolic therapies for osteoporosis in childhood
Leanne Ward
Leanne Ward
S2.3
Thu 19 12:00 SYMPOSIUM 2
Steroid-Associated Osteoporosis in the Pediatric Population
Anu Bashamboo
Anu Bashamboo
S3.1
Thu 19 12:00 SYMPOSIUM 3
Genetics of DSD – do we understand it?
Anna Nordenström
Anna Nordenström
S3.2
Thu 19 12:00 SYMPOSIUM 3
Outcomes in DSD – insight from the DSD life study
Andy Greenfield
Andy Greenfield
S3.3
Thu 19 12:00 SYMPOSIUM 3
Novel insights into sex determination
David Maahs
David Maahs
S4.1
Thu 19 12:00 SYMPOSIUM 4
Hypoglycemia in children with T1D: Past, Present, and Future
Kim	Donaghue
Kim Donaghue
S4.2
Thu 19 12:00 SYMPOSIUM 4
Novel advances in diabetic retinopathy screening and management
Loredana	Marcovecchio
Loredana Marcovecchio
S4.3
Thu 19 12:00 SYMPOSIUM 4
Prediction of renal and cardiovascular complications
Martine Cools
Martine Cools
MTE1.1
Thu 19 14:45 MEET THE EXPERT 1.1
Holistic approach to the individual with DSD
Martine Cools
Martine Cools
MTE1.2
Fri 20 08:30 MEET THE EXPERT 1.2
Holistic approach to the individual with DSD
Mariacarolina Salerno
Mariacarolina Salerno
HDI1.1
Thu 19 14:45 HOW DO I...
How Do I... Manage subclinical hypothyroidism
Maithé Tauber
Maithé Tauber
HDI1.2
Thu 19 14:45 HOW DO I...
How Do I... Manage a patient with Prader Willi and GH at transition - do they benefit as adults?
Francesco Chiarelli
Francesco Chiarelli
HDI1.3
Thu 19 14:45 HOW DO I...
How do I... Manage a child with insulin resistance
Wolfgang Högler
Wolfgang Högler
RFC2.1
Thu 19 14:45 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 2 - Bone, growth plate and mineral metabolism Session 1
Burosumab resulted in better clinical outcomes than continuation with conventional therapy in both younger (1-4 years-old) and older (5-12 years-old) children with X-linked hypophosphatemia
Julia André
Julia André
RFC2.2
Thu 19 14:45 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 2 - Bone, growth plate and mineral metabolism Session 1
Does the treatment with recombinant human growth hormone improve final height in patients affected by X-linked hypophosphatemia?
David Martin
David Martin
RFC2.3
Thu 19 14:45 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 2 - Bone, growth plate and mineral metabolism Session 1
Growth hormone effects on metacarpal bone geometry and bone age in growth hormone-deficient children
David Martin
David Martin
FC2.6
Thu 19 14:45 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 2 - Bone, growth plate and mineral metabolism Session 1
Validation of a new version of BoneXpert bone age in children with congenital adrenal hyperplasia (CAH), precocious puberty (PP), growth hormone deficiency (GHD), Turner syndrome (TS), and other short stature diagnoses
Natascia Lorgi
Natascia Lorgi
RFC2.4
Thu 19 14:45 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 2 - Bone, growth plate and mineral metabolism Session 1
Bone mass and fracture prevalence in childhood brain cancer survivors 2, 5 or 7 years after off therapy
Theo Sas
Theo Sas
RFC2.5
Thu 19 14:45 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 2 - Bone, growth plate and mineral metabolism Session 1
Long term effects of treatment with oxandrolone (Ox) in addition to growth hormone (GH) in girls with Turner syndrome (TS) on bone mineral density in adulthood
Andreas Kyriakou
Andreas Kyriakou
RFC2.6
Thu 19 14:45 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 2 - Bone, growth plate and mineral metabolism Session 1
Impact of pubertal suppression on body composition and bone mineral density in adolescents with gender dysphoria
Agnès Linglart
Agnès Linglart
FC2.1
Thu 19 14:45 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 2 - Bone, growth plate and mineral metabolism Session 1
Continued improvement in clinical outcomes with burosumab, a fully human anti-FGF23 monoclonal antibody: results from a 3-year, phase 2, clinical trial in children with X-linked hypophosphatemia (XLH)
Annemieke Boot
Annemieke Boot
FC2.2
Thu 19 14:45 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 2 - Bone, growth plate and mineral metabolism Session 1
Benefits of long-term burosumab persist in 11 girls with X-linked hypophosphatemia (XLH) who transitioned into adolescence during the phase 2 CL201 trial
Volha Zhukouskaya
Volha Zhukouskaya
FC2.3
Thu 19 14:45 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 2 - Bone, growth plate and mineral metabolism Session 1
Higher dose of burosumab is needed for treatment of children with severe forms of X linked hypophosphatemia
Adalbert Raimann
Adalbert Raimann
FC2.4
Thu 19 14:45 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 2 - Bone, growth plate and mineral metabolism Session 1
New imaging approaches to the quantification of musculoskeletal alterations in X-linked hypophosphatemic rickets (XLH)
Adalbert Raimann
Adalbert Raimann
RFC15.5
Sat 21 09:00 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 15 - Late Breaking Session
De novo missense mutation in SP7 in a patient with cranial hyperostosis, long bone fragility, and increased osteoblast number
Huda Elsharkasi
Huda Elsharkasi
FC2.5
Thu 19 14:45 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 2 - Bone, growth plate and mineral metabolism Session 1
Age and gender-specific reference data for high-resolution magnetic resonance based musculoskeletal parameters in healthy children and young people
Salma Ali
Salma Ali
RFC3.1
Thu 19 14:45 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 3 - Multi-system endocrine disorders
European Registries For Rare Endocrine Conditions (EuRRECa): results from the pilot phase of The Platform For e-Reporting Of Rare Endocrine Conditions (e-REC)
Laura Atger-Lallier
Laura Atger-Lallier
RFC3.2
Thu 19 14:45 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 3 - Multi-system endocrine disorders
Factors affecting loss to follow-up for patients with chronic endocrine conditions during the pediatric period: a cohort study at a reference center for rare diseases
Maha Abdulhadi-Atwan
Maha Abdulhadi-Atwan
RFC3.3
Thu 19 14:45 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 3 - Multi-system endocrine disorders
The founder homozygous NR5A1 gene mutation p.R103Q causes asplenia and severe XY-DSD and XX-DSD in a Palestinian cohort
Shuji Sai
Shuji Sai
RFC3.4
Thu 19 14:45 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 3 - Multi-system endocrine disorders
Peripheral glucocorticoid metabolism may reflect resolution of inflammation in Kawasaki disease
Patrizia Bruzzi
Patrizia Bruzzi
RFC3.5
Thu 19 14:45 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 3 - Multi-system endocrine disorders
Evaluation of endothelial function in childhood standard risk acute lymphoblastic leukemia survivors: role of subclinical markers and identification of preventable factors
Primož Kotnik
Primož Kotnik
RFC3.6
Thu 19 14:45 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 3 - Multi-system endocrine disorders
Prevalence of endocrine complications in Duchenne muscular dystrophy
Maki Fukami
Maki Fukami
FC3.1
Thu 19 14:45 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 3 - Multi-system endocrine disorders
Germline-derived gain-of-function variants of Gsα-coding GNAS gene identified in nephrogenic syndrome of inappropriate antidiuresis: the first report
Francesca Cirillo
Francesca Cirillo
FC3.2
Thu 19 14:45 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 3 - Multi-system endocrine disorders
CFTR loss-of-function has effects on microRNAs (miRNAs) that regulate genes involved in growth, glucose metabolism and in fertility in in vitro models of cystic fibrosis
Maria Velazquez
Maria Velazquez
FC3.3
Thu 19 14:45 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 3 - Multi-system endocrine disorders
Variability in drug metabolizing cytochrome P450 activities caused by human genetic variations in NADPH cytochrome P450 oxidoreductase (POR)
Satoshi Watanabe
Satoshi Watanabe
FC3.4
Thu 19 14:45 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 3 - Multi-system endocrine disorders
Droplet digital PCR is a useful method for detection of mosaic mutations in patients with McCune–Albright syndrome
Samantha Lee
Samantha Lee
FC3.5
Thu 19 14:45 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 3 - Multi-system endocrine disorders
Evaluation of endocrine late effects in survivors of childhood allogeneic hematopoietic stem cell transplantation in Australia database from 1985 to 2011
Joonatan Borchers
Joonatan Borchers
FC3.6
Thu 19 14:45 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 3 - Multi-system endocrine disorders
Severe infections contribute to increased risk of early death in patients with apeced
Kikumi Ushijima
Kikumi Ushijima
RFC1.1
Thu 19 14:45 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 1 - Diabetes and Insulin Session 1
Low prevalence of maternal microchimerism in Japanese children with type 1 diabetes
Zhou Pei
Zhou Pei
RFC1.2
Thu 19 14:45 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 1 - Diabetes and Insulin Session 1
Gabra5 contributes to sexual dimorphism in POMC neural activity and glucose metabolism
Jose Morales
Jose Morales
RFC1.3
Thu 19 14:45 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 1 - Diabetes and Insulin Session 1
The association between IGF-1 levels and nonalcoholic fatty liver disease (NAFLD) in adolescents with type 2 diabetes
Luis Salamanca
Luis Salamanca
RFC1.4
Thu 19 14:45 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 1 - Diabetes and Insulin Session 1
Estimation of MODY frequency and prevalent subtypes in pediatric patients by targeted NGS
Caiqi Du
Caiqi Du
RFC1.5
Thu 19 14:45 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 1 - Diabetes and Insulin Session 1
Decreased circulating levels of MOTS-c in individuals with newly diagnosed type 1 diabetes children
Nancy Elbarbary
Nancy Elbarbary
RFC1.6
Thu 19 14:45 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 1 - Diabetes and Insulin Session 1
An oral trace element supplementation has a potential beneficial effect on glucose homeostasis in transfused patients with β-thalassemia major complicated with diabetes mellitus
Hong Chen
Hong Chen
FC1.1
Thu 19 14:45 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 1 - Diabetes and Insulin Session 1
Insulin resistance leads to mitochondrial dysfunction in hepatocyte
Kyung-Mi Jang
Kyung-Mi Jang
FC1.2
Thu 19 14:45 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 1 - Diabetes and Insulin Session 1
Three new genes (PTPRD, SYT9, and WSF1) related to Korean maturity-onset diabetes in the young (MODY) children decrease insulin synthesis and secretion in human pancreatic beta cells
Amalia Sertedaki
Amalia Sertedaki
FC1.3
Thu 19 14:45 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 1 - Diabetes and Insulin Session 1
Next generation sequencing in Greek MODY patients increases diagnostic accuracy and reveals a high percentage of MODY12 cases
Georgina Williams
Georgina Williams
FC1.5
Thu 19 14:45 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 1 - Diabetes and Insulin Session 1
FADES: A birth cohort to understand the mechanisms underlying accelerated onset of autoimmunity in children with Down’s syndrome
Noah Gruber
Noah Gruber
FC1.6
Thu 19 14:45 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 1 - Diabetes and Insulin Session 1
A novel biochemical marker, fatty acid-binding protein 4, in diabetic ketoacidosis in children
Russell Foster
Russell Foster
PL2
Thu 19 16:30 PLENARY 2
Light, Body Clocks and Sleep: Biology to New Therapeutics
Claus Gravholt
Claus Gravholt
MTE3.1
Thu 19 17:00 MEET THE EXPERT 3.1
Clinical practice guidelines for the care of girls and women with Turner syndrome: proceedings from the 2016 Cincinnati International Turner Syndrome Meeting
Claus Gravholt
Claus Gravholt
MTE3.2
Sat 21 08:00 MEET THE EXPERT 3.2
Clinical practice guidelines for the care of girls and women with Turner syndrome: proceedings from the 2016 Cincinnati International
Julia Rohayem
Julia Rohayem
MTE4.1
Thu 19 17:00 MEET THE EXPERT 4.1
Klinefelter syndrome - when should testosterone be started
Julia Rohayem
Julia Rohayem
MTE4.2
Sat 21 08:00 MEET THE EXPERT 4.2
Klinefelter syndrome - when should testosterone be started
Evangelia Charmandari
Evangelia Charmandari
YB1.1
Thu 19 17:00 YEARBOOK OF PAEDIATRIC ENDOCRINOLOGY 1
Adrenals
Evangelia Charmandari
Evangelia Charmandari
Fri 20 12:30 ESPE AWARDS
ESPE International Outstanding Clinician Award
Evangelia Charmandari
Evangelia Charmandari
Fri 20 12:30 ESPE AWARDS
Outstanding Clinician Award
Khalid Hussain
Khalid Hussain
YB1.2
Thu 19 17:00 YEARBOOK OF PAEDIATRIC ENDOCRINOLOGY 1
Antenatal and Neonatal Endocrinology
Ola Nilsson
Ola Nilsson
YB1.3
Thu 19 17:00 YEARBOOK OF PAEDIATRIC ENDOCRINOLOGY 1
Bone, Growth Plate and Mineral Metabolism
Orit Pinhas-Hamiel
Orit Pinhas-Hamiel
YB1.4
Thu 19 17:00 YEARBOOK OF PAEDIATRIC ENDOCRINOLOGY 1
Type 2 Diabetes, Metabolic Syndrome and Lipids
Ken Ong
Ken Ong
YB1.5
Thu 19 17:00 YEARBOOK OF PAEDIATRIC ENDOCRINOLOGY 1
Editor's Choice
Giorgia Pepe
Giorgia Pepe
RFC5.1
Thu 19 17:00 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 5 - Thyroid
Hurthle cell carcinoma in childhood retrospective analysis of a large series
Marek Niedziela
Marek Niedziela
RFC5.2
Thu 19 17:00 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 5 - Thyroid
Ultrasound features of multinodular goiter in DICER1 syndrome
Alexander Anikiev
Alexander Anikiev
RFC5.3
Thu 19 17:00 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 5 - Thyroid
Experience of thyroid surgery in children with intraoperative neuromonitoring
Sommayya Aftab
Sommayya Aftab
RFC5.4
Thu 19 17:00 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 5 - Thyroid
Thyroid dysfunction in patients following thymus transplantation in a tertiary centre: a 10-year experience
Sommayya Aftab
Sommayya Aftab
RFC9.5
Fri 20 09:30 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 9 - Fetal, neonatal endocrinology and metabolism (to include hypoglycaemia)
Spectrum of neuro-developmental disorders in children with congenital hyperinsulinism due to activating mutations in GLUD1
Eve Stern
Eve Stern
RFC5.5
Thu 19 17:00 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 5 - Thyroid
A novel mutation in the thyroglobulin gene leading to neonatal goiter and congenital hypothyroidism in an Eritrean infant
Fang Yanlan
Fang Yanlan
RFC5.6
Thu 19 17:00 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 5 - Thyroid
Complex single nucleotide polymorphisms in SEPINA 7 lead to TBG deficiency
Claire Wood
Claire Wood
FC5.1
Thu 19 17:00 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 5 - Thyroid
Randomised trial of block and replace versus dose titration antithyroid drug treatment in children and adolescents with thyrotoxicosis
Karolina Stożek
Karolina Stożek
FC5.2
Thu 19 17:00 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 5 - Thyroid
Lower proportion of CD19+IL-10+ and CD19+CD24hiCD27+ IL-10+, but not CD1d+CD5+CD19+CD24+CD27+ IL-10+ B cells in children with autoimmune thyroid diseases
Young Lee
Young Lee
FC5.3
Thu 19 17:00 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 5 - Thyroid
Predominant DICER1 mutations in pediatric follicular thyroid carcinomas
Stéphanie Larrivée-Vanier
Stéphanie Larrivée-Vanier
FC5.4
Thu 19 17:00 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 5 - Thyroid
Thyroid dysgenesis: exome-wide analysis identifies rare variants in genes involved in thyroid development and cancer
Daniela Choukair
Daniela Choukair
FC5.5
Thu 19 17:00 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 5 - Thyroid
Identification of TRPC4AP as a novel candidate gene causing thyroid dysgenesis
Atsushi Suzuki
Atsushi Suzuki
FC5.6
Thu 19 17:00 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 5 - Thyroid
Homozygous loss-of-function mutation in the SLC26A7 gene coding a novel iodide transporter causes goitrous congenital hypothyroidism
Junfen Fu
Junfen Fu
RFC4.1
Thu 19 17:00 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 4 - Fat, metabolism and obesity
Expression of miRNAs in circulating exosomes derived from patients with NAFLD
Xuelian Zhou
Xuelian Zhou
RFC4.2
Thu 19 17:00 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 4 - Fat, metabolism and obesity
Circulating exosomal miRNAs in children’s nonalcoholic steatohepatitis and the correlation with serum transaminase and uric acid
Judit Bassols
Judit Bassols
RFC4.3
Thu 19 17:00 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 4 - Fat, metabolism and obesity
Dysregulated gene expression profile in visceral adipose tissue of juvenile Wistar rats with catch-up growth: association with fat expansion and metabolic parameters
Judit Bassols
Judit Bassols
FC9.3
Fri 20 09:30 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 9 - Fetal, neonatal endocrinology and metabolism (to include hypoglycaemia)
DNA methylation signatures in placenta and umbilical cord: association with maternal obesity
Anna Kirstein
Anna Kirstein
RFC4.4
Thu 19 17:00 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 4 - Fat, metabolism and obesity
The novel phosphatidylinositol-3-kinase (PI3K) inhibitor alpelisib effectively inhibits growth of PTEN haploinsufficient lipoma cells
Feihong Luo
Feihong Luo
RFC4.5
Thu 19 17:00 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 4 - Fat, metabolism and obesity
GDF5 increased white adipose tissue thermogenesis through p38 MAPK signaling pathway in fatty acid-binding protein 4-GDF5 transgenic mice
Christian Roth
Christian Roth
RFC4.6
Thu 19 17:00 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 4 - Fat, metabolism and obesity
Appetite suppressing effects of glucoregulatory peptides devoid of nausea
Christian Roth
Christian Roth
FC4.6
Thu 19 17:00 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 4 - Fat, metabolism and obesity
Brain satiety responses to a meal in children before and after weight management intervention
Mitra Nourbakhsh
Mitra Nourbakhsh
FC4.1
Thu 19 17:00 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 4 - Fat, metabolism and obesity
Involvement of visfatin in adipose tissue fibrosis through modulation of extracellular matrix proteins
Martha Hanschkow
Martha Hanschkow
FC4.2
Thu 19 17:00 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 4 - Fat, metabolism and obesity
Characterization of the adipose progenitor cell marker MSCA1 in normal weight and obese children
Marta Díaz
Marta Díaz
FC4.3
Thu 19 17:00 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 4 - Fat, metabolism and obesity
Circulating growth-and-differentiation factor-15 in early life: relation to prenatal and postnatal size
Anna Sessa
Anna Sessa
FC4.4
Thu 19 17:00 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 4 - Fat, metabolism and obesity
The rs72613567:TA variant in the hydroxysteroid 17-beta dehydrogenase 13 gene reduces liver damage in obese children
Omneya Omar
Omneya Omar
FC4.5
Thu 19 17:00 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 4 - Fat, metabolism and obesity
Leptin gene methylation status in Egyptian infants
Daniele Tessaris
Daniele Tessaris
MTE5.1
Fri 20 08:30 MEET THE EXPERT 5.1
Managing endocrinopathies in McCune-Albright Syndrome
Daniele Tessaris
Daniele Tessaris
MTE5.2
Sat 21 08:00 MEET THE EXPERT 5.2
Managing endocrinopathies in McCune-Albright Syndrome
Zdenek Sumnik
Zdenek Sumnik
MTE6.1
Fri 20 08:30 MEET THE EXPERT 6.1
Management of Diabetic Ketoacidosis
Zdenek Sumnik
Zdenek Sumnik
MTE6.2
Sat 21 14:00 MEET THE EXPERT 6.2
Management of Diabetic Ketoacidosis
Klaus Monicke
Klaus Monicke
MTE8.1
Fri 20 08:30 MEET THE EXPERT 8.1
Management of neonatal hypoglycaemia
Klaus Monicke
Klaus Monicke
MTE8.2
Sat 21 14:00 MEET THE EXPERT 8.2
Management of neonatal hypoglycaemia
Danilo Fintini
Danilo Fintini
YB2.2
Fri 20 08:30 YEARBOOK OF PAEDIATRIC ENDOCRINOLOGY 2
Growth and Growth Factors
Martin Wabitsch
Martin Wabitsch
YB2.3
Fri 20 08:30 YEARBOOK OF PAEDIATRIC ENDOCRINOLOGY 2
Obesity and Weight Regulation
Carla Bizzarri
Carla Bizzarri
YB2.4
Fri 20 08:30 YEARBOOK OF PAEDIATRIC ENDOCRINOLOGY 2
Oncology and Chronic Disease
Jean-Pierre Chanoine
Jean-Pierre Chanoine
YB2.5
Fri 20 08:30 YEARBOOK OF PAEDIATRIC ENDOCRINOLOGY 2
Global Health for the Paediatric Endocrinologist
Jean-Pierre Chanoine
Jean-Pierre Chanoine
Fri 20 14:00 Global Pediatric Endocrinology and Diabetes (GPED) - The Long Winding Road towards Sustainable Access to Affordable Insulin
Introduction
Jing Wu
Jing Wu
RFC6.1
Fri 20 09:30 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 6 - Bone, growth plate and mineral metabolism Session 2
EFTUD2 gene deficiency disturbs maturation of osteoblast and inhibits chondrocyte differentiation via activated p53 signaling
Maria Faienza
Maria Faienza
RFC6.2
Fri 20 09:30 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 6 - Bone, growth plate and mineral metabolism Session 2
High levels of LIGHT/TNFSF14 in Prader–Willi syndrome
Despoina Manousaki
Despoina Manousaki
RFC6.3
Fri 20 09:30 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 6 - Bone, growth plate and mineral metabolism Session 2
Increased burden of common risk alleles in children with a significant fracture history
Aysun Ata
Aysun Ata
RFC6.4
Fri 20 09:30 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 6 - Bone, growth plate and mineral metabolism Session 2
Targeted molecular genetic diagnosis by next generation sequence analysis method and investigation of responsible candidate genes in patients with osteogenesis imperfecta
Jan Lebl
Jan Lebl
RFC6.6
Fri 20 09:30 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 6 - Bone, growth plate and mineral metabolism Session 2
Genetic aetiology predicts growth hormone (GH) treatment outcomes in children born small-for-gestational-age with persistent short stature (SGA-SS). Lessons from a single-centre cohort
Ghazal Hedjazi
Ghazal Hedjazi
FC6.1
Fri 20 09:30 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 6 - Bone, growth plate and mineral metabolism Session 2
Bone tissue characterization of a mouse model of atypical type VI osteogenesis imperfecta reveals hypermineralization of the bone matrix, elevated osteocyte lacunar density and altered vascularity
Alireza Javanmardi
Alireza Javanmardi
FC6.2
Fri 20 09:30 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 6 - Bone, growth plate and mineral metabolism Session 2
Zone wise cell separation methods comparison, based on relative expression of specific growth plate markers in a pig model
Ondrej Soucek
Ondrej Soucek
FC6.3
Fri 20 09:30 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 6 - Bone, growth plate and mineral metabolism Session 2
Decreased trabecular bone mineral density and muscle area at the forearm despite improvement in glycaemic control over 3 years after simultaneous pancreas kidney transplantation
Elif Ozsu
Elif Ozsu
FC6.4
Fri 20 09:30 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 6 - Bone, growth plate and mineral metabolism Session 2
Metabolically unhealthy obese children and adolescents have higher bone mineral density than normal weighted controls but lower than metabolically healthy obeses: no effect of FGF21 levels
Roland Schweizer
Roland Schweizer
FC6.5
Fri 20 09:30 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 6 - Bone, growth plate and mineral metabolism Session 2
No change in bone density during 6 months off GH in adolescents with severe GHD at near-adult height
Isolina Riaño-Galan
Isolina Riaño-Galan
FC6.6
Fri 20 09:30 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 6 - Bone, growth plate and mineral metabolism Session 2
Craniosynostosis in inactivating PTH/PTHrP signaling disorder 2: a non-classical feature to consider
Sarah Ehtisham
Sarah Ehtisham
RFC7.1
Fri 20 09:30 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 7 - Diabetes and Insulin Session 2
Accuracy of glucose sensor estimate of HbA1c in children with type 1 diabetes
Christian Denzer
Christian Denzer
RFC7.2
Fri 20 09:30 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 7 - Diabetes and Insulin Session 2
β-cell function and glucose effectiveness in the development of impaired fasting glucose in obese European children and adolescents
Amany Ibrahim
Amany Ibrahim
RFC7.3
Fri 20 09:30 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 7 - Diabetes and Insulin Session 2
Osteopontin as an early urinary marker of diabetic nephropathy in adolescents with type 1 diabetes mellitus
Hae Jung
Hae Jung
RFC7.4
Fri 20 09:30 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 7 - Diabetes and Insulin Session 2
Handgrip strength correlates with insulin resistance and the metabolic syndrome in children and adolescents: analysis of the Korean National Health and Nutrition Examination Survey 2014-2016
Kineret Mazor-Aronovitch
Kineret Mazor-Aronovitch
RFC7.5
Fri 20 09:30 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 7 - Diabetes and Insulin Session 2
Dual diagnosis of type 1 diabetes and ADHD
Barbara Predieri
Barbara Predieri
RFC7.6
Fri 20 09:30 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 7 - Diabetes and Insulin Session 2
Health-related quality of life and diabetes control in immigrant and Italian children and adolescents with type 1 diabetes and in their parents
Eleni Kotanidou
Eleni Kotanidou
FC7.1
Fri 20 09:30 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 7 - Diabetes and Insulin Session 2
Deployment of a predictive model based on CpG methylation haplotypes analysis on the insulin gene promoter, in a cohort of children and adolescents with type 1 diabetes
Gabor Szinnai
Gabor Szinnai
FC7.2
Fri 20 09:30 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 7 - Diabetes and Insulin Session 2
Copeptin kinetics and its relationship to osmolality during rehydration for diabetic ketoacidosis in children: an observational study
Gabor Szinnai
Gabor Szinnai
YB3.3
Sat 21 08:00 YEARBOOK OF PAEDIATRIC ENDOCRINOLOGY 3
Thyroid
Valentina Chiavaroli
Valentina Chiavaroli
FC7.4
Fri 20 09:30 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 7 - Diabetes and Insulin Session 2
Metabolic syndrome features in pre-pubertal children born after maternal pre-eclampsia
Valentina Chiavaroli
Valentina Chiavaroli
YI1.2
Sat 21 14:00 YOUNG INVESTIGATORS SESSION
The role of the gut microbiome in metabolism
Suna Kılınç
Suna Kılınç
FC7.5
Fri 20 09:30 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 7 - Diabetes and Insulin Session 2
Is the 1-hour post-load glucose level by 75g oral glucose tolerance test a new risk factor in predicting atherosclerosis?
Axel Dost
Axel Dost
FC7.6
Fri 20 09:30 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 7 - Diabetes and Insulin Session 2
2017 American Academy of Pediatrics Clinical Practice Guideline: impact on prevalence of arterial hypertension in children and adolescents with type 1 diabetes mellitus
Murat Karaoglan
Murat Karaoglan
RFC8.1
Fri 20 09:30 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 8 - Pituitary, neuroendocrinology and puberty Session 1
Trade-off between olfactory bulb and eyeball volume in precocious puberty
Ana Canton
Ana Canton
RFC8.2
Fri 20 09:30 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 8 - Pituitary, neuroendocrinology and puberty Session 1
Investigation of imprinting alterations in MKRN3 and DLK1 in a cohort of girls with central precocious puberty through specific DNA methylation analysis
Pavlos Fanis
Pavlos Fanis
RFC8.3
Fri 20 09:30 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 8 - Pituitary, neuroendocrinology and puberty Session 1
Central precocious puberty caused by novel mutations in the promoter and 5′-UTR region of the imprinted MKRN3 gene
Alexsandra Malaquias
Alexsandra Malaquias
RFC8.4
Fri 20 09:30 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 8 - Pituitary, neuroendocrinology and puberty Session 1
Evaluation of puberty in patients with Noonan syndrome and mutations in the RAS/MAPK genes
Leman Kotan
Leman Kotan
RFC8.5
Fri 20 09:30 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 8 - Pituitary, neuroendocrinology and puberty Session 1
CHD7 mutations in patients with anosmic or normosmic idiopathic hypogonadotropic hypogonadism
Maria Consolata Miletta
Maria Consolata Miletta
FC8.1
Fri 20 09:30 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 8 - Pituitary, neuroendocrinology and puberty Session 1
Hypothalamic AgRP neurons drive endurance in food-restricted mice
Santiago Guerra-Cantera
Santiago Guerra-Cantera
FC8.2
Fri 20 09:30 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 8 - Pituitary, neuroendocrinology and puberty Session 1
Analysis of hypothalamic metabolic circuits after normalization of body weight in mice that had been obese due to high fat diet intake
Santiago Guerra-Cantera
Santiago Guerra-Cantera
FC8.4
Fri 20 09:30 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 8 - Pituitary, neuroendocrinology and puberty Session 1
Peripheral and hypothalamic alterations in the insulin like growth factor IGF system in response to high fat diet induced weight gain
Anna Rosenberg
Anna Rosenberg
FC8.3
Fri 20 09:30 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 8 - Pituitary, neuroendocrinology and puberty Session 1
Absence of central adrenal insufficiency in adults with Prader-Willi syndrome
Alessandra Mancini
Alessandra Mancini
FC8.5
Fri 20 09:30 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 8 - Pituitary, neuroendocrinology and puberty Session 1
LGR4-Wnt β-catenin signalling directs GnRH network development, with defects leading to self-limited delayed puberty
Ahreum Kwon
Ahreum Kwon
FC8.6
Fri 20 09:30 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 8 - Pituitary, neuroendocrinology and puberty Session 1
Source and changes in serum level of kisspeptin in female rats at different developmental stages
Takeshi Yamaguchi
Takeshi Yamaguchi
RFC9.1
Fri 20 09:30 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 9 - Fetal, neonatal endocrinology and metabolism (to include hypoglycaemia)
Targeted next-generation sequencing for congenital hypothyroidism with positive neonatal TSH screening results
J Naafs
J Naafs
RFC9.2
Fri 20 09:30 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 9 - Fetal, neonatal endocrinology and metabolism (to include hypoglycaemia)
Age-specific reference values for plasma FT4 and TSH concentrations in healthy, term neonates at day three to seven, and 13 to 15 of life
Rossella Gaudino
Rossella Gaudino
RFC9.3
Fri 20 09:30 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 9 - Fetal, neonatal endocrinology and metabolism (to include hypoglycaemia)
Neonatal screening for congenital hypothyroidism analysis of a large cohort of affected patients 1987 2017 and relationship with perfluoroalkylated substances PFAs in north eastern Italy
Laura Bosch
Laura Bosch
RFC9.4
Fri 20 09:30 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 9 - Fetal, neonatal endocrinology and metabolism (to include hypoglycaemia)
Correlation between genotype and phenotype characteristics in children with congenital hyperinsulinism (CHI) in a specialist centre
Laura Lucaccioni
Laura Lucaccioni
RFC9.6
Fri 20 09:30 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 9 - Fetal, neonatal endocrinology and metabolism (to include hypoglycaemia)
Extra uterine growth restriction (EUGR) in very low birth weight infants: growth recovery and neurodevelopment by the corrected age of 2 years old
Preetha Purushothaman
Preetha Purushothaman
FC9.1
Fri 20 09:30 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 9 - Fetal, neonatal endocrinology and metabolism (to include hypoglycaemia)
Using CRISPR/Cas9 gene editing to study the molecular mechanisms of congenital hyperinsulinism (CHI)
Aashish Sethi
Aashish Sethi
FC9.2
Fri 20 09:30 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 9 - Fetal, neonatal endocrinology and metabolism (to include hypoglycaemia)
Heterozygous insulin receptor (INSR) mutation associated with neonatal hyperinsulinaemic hypoglycaemia and familial diabetes mellitus
Sandra Schulte
Sandra Schulte
FC9.4
Fri 20 09:30 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 9 - Fetal, neonatal endocrinology and metabolism (to include hypoglycaemia)
Prenatal environment and genetic background influence urinary steroid excretion in monozygotic twins with intra-twin birth-weight differences
Susann Empting
Susann Empting
FC9.6
Fri 20 09:30 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 9 - Fetal, neonatal endocrinology and metabolism (to include hypoglycaemia)
[18F]F-DOPA-PET/MRI or /CT in children with congenital hyperinsulinism
Doris Hebenstreit
Doris Hebenstreit
RFC10.1
Fri 20 09:30 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 10 - Sex differentiation, gonads and gynaecology or sex endocrinology
Contemporary surgical approach in CAH 46XX – results from the I-DSD/I-CAH registries
Faruk Hadziselimovic
Faruk Hadziselimovic
RFC10.2
Fri 20 09:30 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 10 - Sex differentiation, gonads and gynaecology or sex endocrinology
Cryptorchid boys with abrogated mini-puberty display differentially expressed genes involved in sudden infant death syndrome
Malika Alimussina
Malika Alimussina
RFC10.3
Fri 20 09:30 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 10 - Sex differentiation, gonads and gynaecology or sex endocrinology
Level of uncertainty in diagnostic evaluation of boys with XY disorders of sex development (DSD)
Jakob Meinel
Jakob Meinel
RFC10.4
Fri 20 09:30 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 10 - Sex differentiation, gonads and gynaecology or sex endocrinology
qPCR screening for Xp21.2 copy number variations in patients with elusive aetiology of 46,XY DSD
Odile Gaisl
Odile Gaisl
RFC10.5
Fri 20 09:30 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 10 - Sex differentiation, gonads and gynaecology or sex endocrinology
Variants in NWD1 gene leading to different degrees of gonadal dysgenesis
Tikva Shore
Tikva Shore
RFC10.6
Fri 20 09:30 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 10 - Sex differentiation, gonads and gynaecology or sex endocrinology
A mutation in the nucleoporin-107 gene causes aberrant Dpp/BMP signaling and XX gonadal dysgenesis
James Oakes
James Oakes
FC10.1
Fri 20 09:30 FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 10 - Sex differentiation, gonads and gynaecology or sex endocrinology
Investigating the roles of androgens in male reproductive development, maintenance and function by characterisation of androgen and cortisol deficient 11ß-hydroxylase mutant zebrafish lines